Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas

Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas Melissa M. Gardner, Sebastian F. Winter, Franziska Stahl, Elizabeth R. Gerstner, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4973431/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 14 Oct, 2024 Read the published version in Journal of Neuro-Oncology → Version 1 posted 9 You are reading this latest preprint version Abstract Purpose Radiation therapy (RT) is an integral treatment component in patients with glioma but associated with neurotoxicity. Proton RT (PRT), as compared with photon RT (XRT), reduces excess radiation to nontarget tissue. We used a retrospective method to evaluate brain imaging metrics of neurotoxicity after treatment with PRT and XRT for glioma. Methods We analyzed brain volume change in thirty-four patients with WHO grade 2–3 gliomas treated with either PRT (n = 17) or XRT (n = 17). Both groups were carefully matched by demographic/clinical criteria and assessed longitudinally for two years post-radiotherapy. Brain volume change was measured as ventricular volume expansion in the tumor free hemisphere (contralateral to RT target) as a proxy indicator of brain volume loss. We further assessed the impact of volumetric changes on cognition in PRT patients, who completed neuropsychological testing as part of an outcome study. Results We found significant ventricular volume increases in the contralesional hemisphere in both groups at two years post-RT (F(1, 31) = 18.45, p < .000, partial η2 = .373), with greater volume change observed in XRT (26.55%) vs. PRT (12.03%) (M = 12.03%, SD = 16.26; F(1,31) = 4.26, p = 0.048, partial η2 = 0.121). Although, there was no group-level change on any cognitive test in PRT treated patients, individual changes on cognitive screening, working memory, processing speed and visual memory tasks correlated with contralesional brain volume loss. Conclusion This study suggests progressive brain volume loss following cranial irradiation, with greater severity after XRT vs PRT. Radiation-induced brain volume loss appears to be associated with measurable cognitive changes on an individual level. Prospective studies are warranted to validate these findings and their impacts on long-term cognitive function and quality of life. An improved understanding of the structural and functional consequences of cranial radiation is essential to develop neuroprotective strategies. Glioma Radiation Therapy Magnetic Resonance Imaging Neurotoxicity Cognition Figures Figure 1 Figure 2 Figure 3 1. Introduction Gliomas are infiltrative primary central nervous system (CNS) tumors that are classified by histologic and molecular criteria [ 1 – 5 ]. Treatment typically consists of maximal safe tumor resection followed by additional tumor directed treatments to slow progression and delay recurrence. Despite advances in cancer therapy to prolong patient survival, WHO grade 2–4 glial tumors are considered incurable neoplasms [ 6 , 7 ]. The treatment for many gliomas includes combined chemotherapy and radiation therapy (RT) [ 8 , 9 ]. While such treatments have been shown to prolong survival, there are known neurotoxic sequelae of such treatments. Neurotoxic effects following RT to the brain include cerebral volume loss [ 10 – 11 ], injury to white matter [ 12 , 13 ], vascular disruption [ 14 – 16 ], and radiation necrosis [ 17 – 19 ], which can greatly impact an individual’s quality of life (QoL). Previous studies from our group have shown that patients with glioblastoma (GBM) who were treated with photon RT (XRT) combined with systemic chemotherapy experience progressive whole brain volume loss as well as grey matter volume loss and white matter integrity changes in the hemisphere contralateral to the tumor/radiation target, suggesting a diffuse neurotoxic effect of such therapy on the brain [ 20 – 22 ]. Cerebral atrophy after RT appears to be irreversible and can contribute to cognitive dysfunction [ 23 – 26 ] through a pattern of progressive cognitive decline [ 27 – 29 ]. Balancing the antineoplastic benefit of cancer directed therapy with these neurotoxic adverse effects is a challenge, given the ultimate goal to improve both quantity and quality of life in glioma survivors [ 5 – 7 ]. There have been mixed outcomes in studies of neurotoxic effects of treatment in patients with lower grade gliomas (LGG) following radiation therapy (RT). While many studies have revealed cognitive deterioration after RT [ 30 – 32 ], some studies have suggested that minimal to no decline occurred [ 33 ] or that confounding variables (e.g., tumor location or laterality) [ 34 ] influenced cognitive performance to a greater extent than treatment-related changes [ 33 , 35 , 36 ]. Indeed, variation in RT characteristics may influence neurotoxicity patterns and degree, including fraction size and total dose [ 35 , 37 – 41 ]. Studies examining the type of RT used in patients with WHO grade 2–3 glioma and the associated treatment-related sequalae over time are warranted. The dosimetric and radiobiological advantages of proton RT (PRT), as compared with photon RT (XRT), restrict radiation delivery to the target region, potentially sparing healthy brain tissue [ 42 – 45 ]. The superior dose distribution of protons [ 46 , 47 ] is due to a radiation beam that travels a finite length and disproportionately delivers much of its dose at the end its path, known as the Bragg Peak, placed in the intended target [ 48 ]. In a prospective study, Brown et al. compared PRT to XRT in patients with GBM, seeking to determine whether PRT would prolong time to cognitive deterioration [ 50 ]. The study found a substantial reduction in radiation dose to brain structures critical to cognitive outcome (e.g., left hippocampus) in the PRT group compared to the XRT cohort. Despite reduced radiation dose to healthy brain tissue in the PRT cohort, there was no difference in cognitive deterioration between groups. Because of the aggressive nature of GBM, the study had limited power due to the rapid deterioration and tumor progression seen in both groups. A prospective, longitudinal study examining cognitive function in adults with LGG receiving PRT showed no decline in cognitive performance at 5 years after treatment, suggesting the possibility of long-term cognitive stability after PRT, but without comparison to XRT treated individuals [ 51 ]. Whether PRT may reduce diffuse neurotoxicity when compared to conventional XRT in patients with LGG remains an area of active investigation. The primary purpose of this study was to longitudinally explore treatment-induced structural and functional neurotoxic complications in adults with lower grade glioma (WHO grades 2–3) following partial cranial radiation treatment. Specifically, we compared brain volume changes for up to two years following PRT vs XRT treatment in carefully matched patient cohorts. We hypothesized that PRT would be associated with less neurotoxicity than XRT, as assessed by brain volume loss contralateral to the glioma target. In addition, taking advantage of prospective longitudinal neuropsychological assessment that had been conducted in the cohort of PRT patients, we sought to explore the relationships between contralesional volumetric changes and cognitive performance over a two-year time period following treatment. 2. Materials and Methods A secondary retrospective case-control study design was used to investigate demographic, clinical (e.g., treatment variables), and histopathological data in a total of 34 adult patients with lower grade glioma (WHO grades 2–3) treated with either XRT or PRT at the Massachusetts General Hospital (MGH) between 11/1998–10/2017. Patients treated with PRT were identified from ongoing longitudinal single-arm outcome studies at our institution (NCT01358058, NCT03286335), which included routine brain MRI and serial neuropsychological assessments. Patients treated with XRT were identified from an archival database from the Departments of Radiation Oncology and the Division of Neuro-Oncology at MGH. All PRT patients signed informed consent for participation in the outcome studies enumerated above. The XRT patient data was gathered under a Mass General Brigham IRB approved research protocol for secondary retrospective analyses of medical record data. All research procedures were conducted in accordance with the Declaration of Helsinki [ 52 ] As indicated above, patients treated with XRT had not completed neuropsychological assessment as part of their routine care, so only PRT patients were included in the detailed cognitive analyses. Inclusion criteria for all patients were: (a) pathologically confirmed grade 2 or grade 3 glioma as defined by the World Health Organization (pathology records included the WHO classification criteria that were in place at the time of diagnosis and were re-classified to meet the 2021 classification based on available data), (b) tumor burden limited to one hemisphere (e.g., tumors did not cross midline to minimize brain volume changes associated with tumor growth or regression after treatment), (c) age 18 years or older, (d) partial cranial radiation therapy (PRT or XRT) delivered at MGH, (e) availability of contrast-enhanced axial brain magnetic resonance imaging scans (e.g., MPRAGE, BRAVO, or thick slice T1 weighted MRI) at baseline (within eight weeks after completion of radiation therapy) as well as at yearly intervals or more frequently (part of routine cancer surveillance screening), and (f) a minimum of two years progression free survival following RT. To limit sampling bias, XRT patients were closely matched to “case-control” PRT patients using a carefully developed eleven-tiered set of criteria: age, sex, tumor type, tumor location, laterality of tumor, isocitrate dehydrogenase (IDH) 1 mutation status, 1p/19q co-deletion status, concurrent chemotherapy, adjuvant chemotherapy, total radiation dose, and number of radiation fractions. Participants were first matched on an individual level, followed by a group match for patients (n = 6) that did not match on all eleven variables. Structural MRI scans were collected for patients at baseline, one year, and at two years after RT. When available, thin-slice (1mm) imaging (e.g., MPRAGE, BRAVO, and T1) was used for volume quantification; thick-slice (6mm) images were used for those cases without thin-slice imaging. As in our prior studies [ 20 , 53 ], we measured volume change in the lateral ventricle in the hemisphere contralateral to the tumor as an index of diffuse cerebral volume loss. Ventricular segmentation was performed manually using Slicer (Version 4.10.2) to generate a 3D model of the contralesional ventricle, as illustrated in Fig. 1 . The manual segmentation process was carried out by two trained research technicians following extensive training from board-certified neuro-oncologists (J.D. and E.G.) to ensure accurate identification of the limits of the ventricle. Each researcher identified the area of interest or ventricular space on a single axial slice using a “point and click” method to place a “seed” in the ventricular space and then used the “grow from seeds” function in Slicer to fill in all areas of the ventricle across slices. The program computed volume as the product of voxel size in the individual patient’s image space multiplied by the number of voxels labeled as included in the ventricle. Inter-rater reliability was evaluated by random selection of ventricular measurements for ten patients at each time point using the same method. INSERT FIGURE 1 HERE As noted above, PRT patients completed neurocognitive assessment at baseline (e.g., after the surgical resection and before start of radiotherapy) and follow-up (e.g., two years after baseline). All neuropsychological evaluations were carried out by a neuropsychologist (J.S.) with testing assistance from a psychometrist. The detailed neuropsychological evaluation included cognitive screening measures, attention/working memory, processing speed, executive functioning, language, memory, and measures of depression and anxiety (See Supplemental Table 1 for complete list of tests). Embedded within the assessment was the "clinical trial battery composite” (CBTC) which generates a composite score routinely used in large scale clinical trials of cognitive outcomes in patients with brain tumors [ 54 , 55 ]. The CTBC is the mean of the Z-scores of the following six metrics: Controlled oral word association (COWA), Trail Making Test parts A and B (TMT-A and B), and total recall, delayed recall, and recognition discrimination scores from the Hopkins Verbal Learning Test-Revised (HVLT-R)[ 54 ] Normative data (e.g., conversion to z-scores using published test norms) for neuropsychological assessment allows for a standardized comparison of individual performance while controlling for demographic factors (e.g., age, education). In repeat or serial cognitive assessment, it is controversial whether discrete norms yield invalid or additional error [ 56 , 57 ]; therefore, raw scores were used in analyses assessing change over time. Linear regression and correlation coefficients were calculated to examine the relationship between change in ventricular volumes and change in cognitive performance in patients treated with PRT. Non-parametric tests were used for binary variables indicating cognitive deterioration. Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS-29). Descriptive statistics were calculated for demographic, diagnostic and treatment data for the two study groups (PRT and XRT) and compared with non-parametric analyses including the Mann-Whitney U-test of independence to evaluate their equivalence. Percent change in lateral ventricle volume between the two study groups was evaluated using a repeated-measures ANOVA with treatment as the between groups factor (XRT and PRT) and time (year 1 and 2 from baseline) as the within patients variable. Paired t-tests and simple linear regression analyses were used to test overall change from baseline to follow-up. Associations between lateral ventricle volume changes and measures of neurocognitive functioning, mood and anxiety were explored using correlations and linear regressions. To examine the relationship between ventricular volume and cognitive decline, the mean change in raw scores for each cognitive test was determined and those patients whose cognitive decline was 1 standard deviation or more below the mean change for the group were defined as “decliners” on that test. The number of cognitive tests showing a decline was tabulated for each individual and plotted into a simple linear regression. An alpha of .01 was used to control for multiple comparisons of the neurocognitive baseline and follow-up analyses and should be interpreted as exploratory. 3. Results 3.1. Demographics Over 80% (n = 28/34) of patients were precisely matched at an individual level based on all eleven specified criteria. Six additional patients differed in no more than two of the eleven variables and were added to the total sample (shown in Table 1 ). Following this matching process, 34 patients with progression-free WHO grade 2 or 3 gliomas were included with 17 patients in each cohort (17 PRT matched with 17 XRT). As shown in Table 1 , there were no statistically significant differences between groups on demographics, tumor characteristics or treatment variables. Review of clinically acquired brain imaging confirmed that patients remained free from tumor progression during the two-year study period. INSERT Table 1 HERE Table 1 Summary of patient characteristics, treatment specifics, and clinical outcome. Patient characteristics Total cohort XRT PRT p value for difference between groups No of patients included 34 17 17 Demographics % sex ratio (m/f) 56 / 44 59 / 41 53 / 47 X 2 = 0.119, p = 0.730 Median Age at diagnosis (yrs) 39.6 38.6 39.6 t=-0.115, p = 0.126 Tumor specifics Intracranial Location X 2 = 4.877, p = 0.431 % left / right 56 / 44 47 / 53 65 / 35 X 2 = 1.074, p = 0.300 % frontal (N) 50.0 (17) 47.1 (8) 52.9 (9) % temporal (N) 32.4 (11) 41.2 (7) 23.5 (4) % insular (N) 5.9 (2) 0 (0) 11.8 (2) % thalamic (N) 5.9 (2) 5.9 (1) 5.9 (1) % parietal (N) 2.9 (1) 0 (0) 5.9 (1) % cerebellopontine angle (N) 2.9 (1) 5.9 (1) 0 (0) WHO Grade % (N) X 2 = 0.582, p = 0.748 2 64.7 (22) 58.8 (10) 70.6 (12) 3 29.4 (10) 35.3 (6) 23.5 (4) low grade, not otherwise specified 5.9 (2) 5.9 (1) 5.9 (1) Histopathology X 2 = 0.183, p = 0.913 % astrocytoma* (N) 73.5 (25) 76.5 (13) 70.6 (12) % oligodendroglioma (N) 20.6 (7) 17.6 (3) 23.5 (4) % low grade astrocytoma, not otherwise specified 5.9 (2) 5.9 (1) 5.9 (1) Molecular-genetic profile % IDH1 mutant (N) 82.4 (28) 76.5 (13) 88.2 (15) X 2 = 0.81, p = 0.368 % 1p19q co-deleted (N) 37.0 (10/27) 38.5 (5/13) 35.7 (5/14) X 2 = 0.02, p = 0.883 % p53 mutated (N) 37.0 (10/27) 54.5 (6/11) 25.0 (4/16) X 2 = 6.367, p = 0.041 % ATRX loss 42.1 (8/19) 33.3 (2/6) 46.2 (6/13) X 2 = 6.085, p = 0.048 % MGMT promoter methylated (N) 50.0 (6/12) 42.9 (3/7) 60.0 (3/5) X 2 = 1.238, p = 0.538 Clinical status % w/ cardiovascular comorbidities 61.8 70.6 (12) 52.9 (9) X 2 = 3.84, p = 0.147 % w/ recurrence prior to RT (N) 35 (12) 24 (4) 47 (8) X 2 = 2.06, p = 0.151 Median KPS baseline pre-RT 90 90 90 t = 1.343, p = 0.165 Median KPS 2 years post-RT 90 95 90 t=-0.026, p = 0.475 Treatment details Extent of surgical resection X 2 = 5.727, p = 0.126 % GTR (N) 8.8 (3) 5.9 (1) 11.8 (2) % NTR (N) 17.6 (6) 0 (0) 35.3 (6) % STR (N) 32.4 (11) 29.4 (5) 35.3 (6) % PR (N) 17.6 (6) 17.6 (3) 17.6 (3) % Biopsy only (N) 23.5 (8) 41.2 (7) 5.9 (1) X 2 = 5.1, p = 0.024 Radiotherapy Regimen n/a % Photons (N) 50 (17) 100 (17) N/A % IMRT (N) 29.4 (5/17) N/A % VMAT (N) 17.7 (3/17) N/A % 3D CRT (N) 5.9 (1/17) N/A % IFRT, not otherwise specified 47.1 (8/17) % Protons (N) 50 (17) N/A 100 (17) Median Dose in Gy (range) 54 (9) 59.4 (9) 54(RBE) (5.4) t = 1.92, p = 0.065 Median No. Fractions (range) 30 (5) 33 (5) 30 (3) t = 1.41, p = 0.167 Median Fraction size in Gy 1.8 1.8 1.8(RBE) t = 1.00, p = 0.325 Systemic Treatment % w/ neoadjuvant Ctx (N) 14.7 (5) 17.6 (3) 11.8 (2) X 2 = 5.034, p = 0.412 % w/ concurrent Ctx (N) 32.4 (11) 35.5 (6) 29.4 (5) X 2 = 0.134, p = .714 % w/ adjuvant Ctx (N) 67.6 (23) 58.8 (10) 76.5 (13) X 2 = 1.209, p = 0.271 Clinical outcome Median PFS post-RT in years (SD) 5.0 (3.69) 4.7 (4.95) 5.1 (1.26) p = .134, CI-5.52 -8.3 % w/ recurrence post-RT (N) 44.1 (15) 58.8 (10) 29.4 (5) X 2 = 2.43, p = 0.119 Abbreviations: ATRX = alpha-thalassemia/mental retardation, X-linked; Ctx = chemotherapy; f = female; GTR = gross total resection; IDH1 = isocitrate dehydrogenase 1; IFRT = involved-field radiation therapy; IMRT= intensity-modulated radiation therapy; KPS = Karnofsky Performance Satus Scale; m = male; MGMT = Methylguanine methyltransferase; NTR = near total resection; PFS = progression-free survival; PR = partial resection; RT = radiotherapy; SD = standard deviation; STR = subtotal resection; VMAT = volumetric modulated arc therapy; WHO = World Health Organization; yrs = years *The majority (n = 21) of tumors were classified as “Astrocytoma, IDH mutant” as per WHO 2021 classification. In the remainder (n = 4), imaging, histopathology, and disease course were consistent with grade 2/3 astrocytoma although detailed molecular information were not available given the retrospective nature of the study. Table 1 reproduced with permission from Winter et al., 2024 [58] 3.2. Volumetric Analysis The preferred brain MRI sequence for measurement of ventricular volume is a 3-dimensional high resolution T1-weighted image with 1mm slice thickness (e.g., MPRAGE, BRAVO). However, this sequence was not always obtained in standard clinical brain MRI studies between 1998 and 2017. Although the PRT cohort had high resolution T1-weighted images with 1mm slices available for all 17 patients at both time points (i.e., baseline and follow-up), seven XRT patients did not have high resolution imaging available at both time points. Ventricular volumes for these seven XRT patients were measured using T1-weighted images with 6 mm slice thickness. The Shapiro-Wilk tests revealed the raw volumetric MRI data at baseline (p = 0.069 and 0.046) was normally distributed. However, the difference between ventricular volume measurements in those with 1mm MRI slices vs 6mm MRI slices was statistically significant (F([ 1 , 32 ] = 6.66, p = .015). To control for the systematic difference in raw volumes between different imaging types, we used the same image type (e.g., thick slice images) at both the baseline and follow up time points for the 7 patients who did not have thin slice imaging available at one of those points. For subsequent analyses, we calculated the percent change in ventricular volume for each patient using images with identical geometry at baseline and two-year follow up (ventricular volume at two years minus ventricular volume at baseline divided by ventricular volume at baseline * 100). An ANOVA showed no significant difference between image types (thick vs thin slice) using percent volume change at one year (F[ 1 , 32 ] = 0.077, p = .783) as the dependent variable, with a normal distribution and no outliers. Ventricular volume calculations using high resolution (thin slab) images were highly reliable, with intra-class correlations coefficients (ICC) showing excellent agreement between raters at baseline (ICC = .969) and follow-up (ICC = .931). A repeated-measures ANOVA found a main effect of time, whereby overall ventricular volume was significantly greater (F(1, 31) = 18.45, p = < .000, partial η2 = .373) in all patients after two years. There was also a main effect of treatment type; the XRT group had greater percent change in volume of the contralesional lateral ventricle (M = 26.55%, SD = 13.46%) than the PRT group (M = 12.03%, SD = 16.26; F(1,31) = 4.26, p = 0.048, partial η2 = 0.121). A statistically significant interaction effect (1,31) = 10.16, p = 0.003 partial η2 = .247 was found between PRT and XRT over time, where patients treated with photons showed greater change at 2 years, as shown in Fig. 2 . INSERT FIGURE 2 HERE 3.3. Neurocognitive, emotional, and behavioral assessment Exploratory analyses were conducted to examine changes in neuropsychological performance over time (i.e., from baseline to follow-up) for 16 of the 17 patients in the PRT group (one patient did not undergo cognitive testing). Descriptive statistics are presented in Table 2 . INSERT Table 2 HERE Table 2 Neurocognitive domains and tests scores for exploratory analyses Baseline Mean (SD) Follow-up Mean (SD) Cognitive Δ Mean (SD) Correlation with Δ Volume (r, p) Cognitive Domain Cognitive test(s) N = 16 N = 16 N = 16 Cognitive Screen MMSE 29.19 (1.33) 29.19 (1.33) -0.06 (1.53) (r=-0.459, p = 0.073) ACE-R 93.63 (6.1) 93.63 (6.1) 0.69 (4.13) ( r = − .793 , p = < 0.001) Language Boston Naming Test 55.5 (4.32) 55.5 (4.32) 1.13 (2.34) ( r = − .606 , p = 0.013) Auditory Naming Test 49.25 (1.29) 49.25 (1.29) 0.25 (1.13) (r=-0.316, p = 0.234) Semantic Fluency: Animal Naming 22.19 (6.42) 22.19 (6.42) 0.38 (4.38) (r=-0.308, p = 0.246) Attention | Working Memory WAIS-IV ; Digit Span 27.13 (6.12) 27.13 (6.12) -1.13 (3.4) ( r = − .609 , p = 0.012) WMS-III Spatial Span 16.25 (3.61) 16.25 (3.61) -0.44 (2.87) (r=-0.328, p = 0.215) Auditory Consonant Trigrams 34.75 (6.83) 32.38 (8.72) -2.37 (5.84) (t = 1.626, p = 0.125) Executive Function | Processing speed WAIS-IV; Coding 70.5 (20.77) 70.5 (20.77) -2.38 (9.97) ( r = − .704 , p = 0.002) Trail Making Test; Part A 26.81 (9.36) 26.81 (9.36) -0.06 (6.65) (r = 0.258, p = 0.335) Trail Making Test; Part B 59.63 (26.15) 59.63 (26.15) 1.25 (19.77) (r = 0.473, p = 0.064) Controlled Oral Word Association Test 43.75 (12.41) 43.75 (12.41) 4.13 (7.86) (r=-0.06, p = 0.826) Verbal Memory HVLT-R Total Recall 24.56 (5.45) 24.56 (5.45) -2.06 (6.48) (r=-0.48, p = 0.06) HVLT-R Delayed Recall 8.06 (2.57) 8.06 (2.57) 0.06 (4.19) (r=-0.433, p = 0.094) HVLT-R Recognition Index 10.81 (1.38) 10.81 (1.38) 0.13 (1.54) (r=-0.479, p = 0.061) Visual Memory 24.11 (6.8) 30.06 (2.7) -3.40 BVMT-R Total Recall 23.56 (6.89) 23.56 (6.89) -0.44 (5.93) (r=-0.447, p = 0.082) BVMT-R Delayed Recall 8.81 (2.23) 8.81 (2.23) -0.38 (2.36) (r=-.549, p = 0.027) BVMT-R Recognition Index 5.81 (0.75) 5.81 (0.75) -0.13 (0.81) (r=-.596, p = 0.015) Clinical Trial Battery Composite Score † -0.18 (0.84) -0.19 (0.74) -0.01 (0.72) (r=-0.47, p = 0.066) Emotional & Behavioral Functioning Beck Anxiety Inventory 3.63 (3.96) 3.63 (3.96) -1 (4.24) (r = .325, p = 0.219) Beck Depression Inventory 5.13 (6.33) 5.13 (6.33) -0.69 (3.74) (r = 0.163, p = 0.546) Abbreviations (PRT cohort only): MMSE = Mini Mental State Examination; ACE-R = Addenbrooke's Cognitive Examination - Revised; WAIS-IV = Wechsler Adult Intelligence Scale − 4th edition; WMSIII = Wechsler Memory Scale—3rd edition; ACT = Auditory Consonant Trigrams; HVLT-R = Hopkins Verbal Learning Test – Revised; BVMT-R = Brief Visuospatial Memory Test – Revised; Change = Δ Statistically significant (p < 0.05) †Standardized z scores Contralesional ventricular volume and baseline neurocognitive scores did not significantly correlate prior to the start of treatment. Paired t-tests showed that there was no statistically significant change between baseline and follow-up on any of the neurocognitive assessment measures at the group level . However, at an individual level significant associations were observed between ventricular volume increases and declines on several cognitive test scores. As shown in Fig. 3 , volume change was moderately to strongly inversely associated with changes in ACE-R (r = − .793, p = < 0.001), digit span (r = − .609, p = 0.012), coding (r = − .704, p = 0.002), naming (r = − .606, p = 0.013), visual memory delayed recall (r = − .549, p = 0.027) and visual recognition discrimination index (r = − .596, p = 0.015). Increase in ventricular volume showed a moderate negative correlation approaching statistical significance with the CTBC Z-score (r = -0.470; p = 0.066). Emotional and behavioral functioning tests did not show a significant relationship with volumetric change at any time point (baseline or follow-up). INSERT FIGURE 3 HERE Ventricular enlargement also demonstrated sensitivity to the number of tests on which an individual showed cognitive decline (defined as a decline of greater than 1 SD more than the group mean change). Linear regression indicated that ventricular enlargement accounted for 60.3% of the variation in cognitive deterioration (F(1,14) = 21.3, p < 0.001) from baseline to follow-up. The strongest relationships between volume loss and cognitive deterioration were seen on the coding and digit span tests (partial r’s = -0.70 and − .61, respectively; p’s < 0.01; see Table 3 ). INSERT Table 3 HERE Table 3 Neurocognitive domains and tests scores for exploratory analyses Baseline Mean (SD) Follow-up Mean (SD) Cognitive Δ Mean (SD) Correlation with Δ Volume (r, p) Cognitive Domain Cognitive test(s) N = 16 N = 16 N = 16 Cognitive Screen MMSE 29.19 (1.33) 29.19 (1.33) -0.06 (1.53) (r=-0.459, p = 0.073) ACE-R 93.63 (6.1) 93.63 (6.1) 0.69 (4.13) ( r = − .793 , p = < 0.001) Language Boston Naming Test 55.5 (4.32) 55.5 (4.32) 1.13 (2.34) ( r = − .606 , p = 0.013) Auditory Naming Test 49.25 (1.29) 49.25 (1.29) 0.25 (1.13) (r=-0.316, p = 0.234) Semantic Fluency: Animal Naming 22.19 (6.42) 22.19 (6.42) 0.38 (4.38) (r=-0.308, p = 0.246) Attention | Working Memory WAIS-IV ; Digit Span 27.13 (6.12) 27.13 (6.12) -1.13 (3.4) ( r = − .609 , p = 0.012) WMS-III Spatial Span 16.25 (3.61) 16.25 (3.61) -0.44 (2.87) (r=-0.328, p = 0.215) Auditory Consonant Trigrams 34.75 (6.83) 32.38 (8.72) -2.37 (5.84) (t = 1.626, p = 0.125) Executive Function | Processing speed WAIS-IV; Coding 70.5 (20.77) 70.5 (20.77) -2.38 (9.97) ( r = − .704 , p = 0.002) Trail Making Test; Part A 26.81 (9.36) 26.81 (9.36) -0.06 (6.65) (r = 0.258, p = 0.335) Trail Making Test; Part B 59.63 (26.15) 59.63 (26.15) 1.25 (19.77) (r = 0.473, p = 0.064) Controlled Oral Word Association Test 43.75 (12.41) 43.75 (12.41) 4.13 (7.86) (r=-0.06, p = 0.826) Verbal Memory HVLT-R Total Recall 24.56 (5.45) 24.56 (5.45) -2.06 (6.48) (r=-0.48, p = 0.06) HVLT-R Delayed Recall 8.06 (2.57) 8.06 (2.57) 0.06 (4.19) (r=-0.433, p = 0.094) HVLT-R Recognition Index 10.81 (1.38) 10.81 (1.38) 0.13 (1.54) (r=-0.479, p = 0.061) Visual Memory 24.11 (6.8) 30.06 (2.7) -3.40 BVMT-R Total Recall 23.56 (6.89) 23.56 (6.89) -0.44 (5.93) (r=-0.447, p = 0.082) BVMT-R Delayed Recall 8.81 (2.23) 8.81 (2.23) -0.38 (2.36) (r=-.549, p = 0.027) BVMT-R Recognition Index 5.81 (0.75) 5.81 (0.75) -0.13 (0.81) (r=-.596, p = 0.015) Clinical Trial Battery Composite Score † -0.18 (0.84) -0.19 (0.74) -0.01 (0.72) (r=-0.47, p = 0.066) Emotional & Behavioral Functioning Beck Anxiety Inventory 3.63 (3.96) 3.63 (3.96) -1 (4.24) (r = .325, p = 0.219) Beck Depression Inventory 5.13 (6.33) 5.13 (6.33) -0.69 (3.74) (r = 0.163, p = 0.546) Abbreviations (PRT cohort only): MMSE = Mini Mental State Examination; ACE-R = Addenbrooke's Cognitive Examination - Revised; WAIS-IV = Wechsler Adult Intelligence Scale − 4th edition; WMSIII = Wechsler Memory Scale—3rd edition; ACT = Auditory Consonant Trigrams; HVLT-R = Hopkins Verbal Learning Test – Revised; BVMT-R = Brief Visuospatial Memory Test – Revised; Change = Δ Statistically significant (p < 0.05) †Standardized z scores 4. Discussion To our knowledge, the current study represents the first controlled comparison of PRT and XRT effects on brain volume and associated cognitive change over two years in patients with LGG. This study found that both PRT and XRT treatment for LGG were associated with substantial and progressive ventricular volume expansion over two years following treatment. This change was significantly greater in patients treated with XRT, with a mean percent change in lateral ventricular volume expansion contralateral to the tumor of 26.55% compared to 12.03% in the PRT group. Exploratory analyses examining correlations between ventricular volume change and cognition over time showed significant relationships on tests of global cognitive function, attention, working memory, processing speed, language, and visual memory. Measures of working memory and processing speed were strongly associated with volume change, whereas changes on a commonly used verbal memory measure, the HVLT-R, were not associated with volumetric change. This finding is of particular interest given the CTBC score includes measures from the HVLT-R but not from coding and digit span. Thus, studies limited to only the CTBC measures may be missing diffuse changes that impact attention/working memory and processing speed. Further dissection of simple attention (digit span forward) vs. working memory (digit span backward/sequencing) is warranted. The progressive brain volume loss in LGG patients treated with RT identified in this study supports previous findings from studies in GBM patients, which have demonstrated progressive brain volume loss following combined XRT and chemotherapy [ 20 , 21 ]. Our findings are also consistent with a study conducted by Petr et al. (2017), examining brain volume loss and cerebral perfusion patterns in patients with GBM treated with either XRT or PRT. However, in the Petr et al. (2017) study, significant cerebral atrophy was seen only in the non-tumor hemisphere of patients treated with XRT but not in patients treated with PRT [ 11 ]. The location of high and low dose regions across conditions (PRT and XRT) predicted regional volume loss, although the authors identified that patient age was a confounding variable contributing to this finding. The careful age-match in our study suggests that greater ventricular volume increase is likely related to XRT treatment rather than age. Furthermore, in a concurrent study using this sample of patients, we have demonstrated unique patterns of white matter damage associated with each radiation modality, with increased evolution of diffuse leukoencephalopathy and cerebral microbleeds in the contralesional hemisphere in XRT as compared with PRT treated patients [ 58 ]. It is likely that both white and grey matter changes are contributing to the overall cerebral volume loss and ventricular expansion demonstrated here. Few studies have integrated cognitive outcomes in the examination of radiation-associated neurotoxicity. A recent phase II trial did not find a difference in cognitive failure rates following proton compared to photon therapy 6 months after treatment in patients with glioblastoma (GBM) when assessed at a group level [ 59 ]. Despite the limited follow period (6 months), a significant difference in patient reported fatigue was observed, favoring the PRT (24%) over XRT (58%) arm. Our study suggests that the effects of treatment may become more apparent over time in progression free survivors of lower grade gliomas, with relative reduction of neurotoxic sequelae in those treated with PRT. Given the significant ventricular enlargement in the XRT group two years after treatment, analysis of the associated changes in cognitive functioning is a critical consideration. It is important to highlight that there was substantial variability in lateral ventricular volume changes over 2 years in both the PRT and XRT cohort. Our findings suggest that individuals who experience a higher degree of brain volume loss are more likely to have cognitive deterioration. Given the relationship between volume change and cognition, further examination of risk factors for lateral ventricular volume increase/brain volume loss in people undergoing RT is needed. Neurotoxicity of treatment is an important factor to consider in optimizing long term outcomes. RT has been a core component of treatment for patients with LGG for many years [ 60 ], yet the treatment landscape is evolving [ 61 ] and the value of PRT over XRT-based therapies is actively being investigated in the context of their relative risks and costs [ 62 ]. Observing a cohort of patients with less aggressive gliomas (i.e., grade 2–3, IDH-mutant), putatively less toxic treatment (e.g., IDH inhibitor therapy or temozolomide without radiation therapy) or favorable demographic variables (e.g., age, cognitive reserve, cardiovascular risk factors) would provide additional data on the effects of brain volume loss on a population with expected prolonged overall survival rates. It is also important to evaluate if changes in ventricle volume and the associated changes in cognitive functioning generalize across conditions (e.g., at different timepoints as well as domain specific cognitive change and at what timepoint). Limitations of our study include its retrospective design, relatively small sample size, and the fact that cognitive assessment was available only for the PRT group. Consideration for tumor laterality and its relationship with cognitive performance or additional treatment related variables (e.g., extent of surgical history at baseline) would be beneficial. Future designs would benefit from securing uniform imaging and comparing the absolute volumetric change between groups. Integration of more advanced imaging, such as diffusion tensor imaging to evaluate white matter integrity and resting state functional MRI to measure functional connectivity, would further elucidate the underlying mechanisms of these brain changes [ 63 ]. Additionally, extending volumetric surveillance past two years would inform researchers and healthcare providers about the long-term implications and progressive pattern of treatment related neurotoxicity. A randomized controlled trial is considered the gold standard for comparing two groups when evaluating the effectiveness and impact of treatment interventions as it offers the most rigorous method for hypothesis testing. While randomization was not feasible in this study, it is important to note that a randomized controlled trial is not always achievable as the treating physicians ethically must maintain clinical equipoise in addition to following known treatment standards. The ongoing cooperative group NRG Oncology BN005 study addresses this concern by randomizing IDH-mutant LGG patients between photon and proton therapy [ 64 ] and includes cognitive assessment measures, which may provide further opportunity to study these issues. 5. Conclusions Understanding the pattern of progressive neural injury following RT is a critical step to develop future neuroprotective strategies and to ultimately improve QoL and survivorship in patients with glioma. This retrospective case-matched study identified that ventricular volume in patients with WHO grade 2–3 gliomas receiving radiation therapy increased over two years following treatment. Patients treated with XRT had significantly greater change over time than those treated with PRT. The secondary analyses suggest that volume change correlated significantly with cognitive deterioration in the PRT group. Prospective studies are warranted to validate these findings in larger cohorts and understand the long-term impacts of different radiation modalities on brain structure and function. Declarations Funding Statement This research received no external funding. Competing Interest Statement Michael W. Parsons serves as a consultant to Servier Pharmaceuticals. Author Contribution Statement: All authors contributed to the study conception and design, and results interpretation. Material preparation, data collection and analysis were performed by Melissa M. Gardner, Sebastian F. Winter, Franziska Stahl and Michael W. Parsons. The first draft of the manuscript was written by Melissa M. Gardner and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Data Availability Statement Research data for this work are available upon request to the corresponding author by any qualified investigator. Ethics Approval This study was performed in line with the principles of the Declaration of Helsinki. All research procedures were conducted with the approval of the Institutional Review Board of Mass General Brigham. References Louis DN, Perry A, Burger P (2014) International Society Of Neuropathology–Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. Brain Pathol 24:429–435 Louis DN, Ohgaki H, Wiestler OD (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109 Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncol 22:1–96. 10.1093/neuonc/noaa200 Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro-Oncol 21:1–100. 10.1093/neuonc/noz150 Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro-Oncol 23:1231–1251. 10.1093/neuonc/noab106 Taphoorn MJB, Sizoo EM, Bottomley A (2010) Review on Quality of Life Issues in Patients with Primary Brain Tumors. Oncologist 15:618–626. 10.1634/theoncologist.2009-0291 Boele FW, Klein M, Reijneveld JC, Verdonck-de Leeuw IM, Heimans JJ (2014) Symptom Management and Quality of Life in Glioma Patients. CNS Oncol 3:37–47. 10.2217/cns.13.65 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987–996. 10.1056/NEJMoa043330 Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. Lancet Oncol 10:459–466. 10.1016/S1470-2045(09)70025-7 Prust M (2015) Standard Chemoradiation for Glioblastoma Results in Progressive Brain Volume Loss. Harvard University Petr J, Platzek I, Hofheinz F (2018) Photon vs. Proton Radiochemotherapy: Effects on Brain Tissue Volume and Perfusion. Radiother Oncol 128:121–127 Rauch PJ, Park HS, Knisely JPS, Chiang VL, Vortmeyer AO (2012) Delayed Radiation-Induced Vasculitic Leukoencephalopathy. Int J Radiat Oncol 83:369–375 Terziev R, Psimaras D, Marie Y, Feuvret L, Berzero G, Jacob J, Dehais C, Bompaire F, Mueller W, Kinnersley B et al (2021) Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. Sci Rep 11:10176. 10.1038/s41598-021-89216-1 Winter SF, Klein JP, Vaios EJ (2021) Clinical Presentation and Management of SMART Syndrome. Neurology 97:118–120 Aizer AA, Du R, Wen PY, Arvold ND (2015) Radiotherapy and Death from Cerebrovascular Disease in Patients with Primary Brain Tumors. J Neurooncol 124:291–297 Roongpiboonsopit D, Kuijf HJ, Charidimou A (2017) Evolution of Cerebral Microbleeds after Cranial Irradiation in Medulloblastoma Patients. Neurology 88:789–796 Winter SF, Loebel F, Loeffler J (2019) Treatment-induced brain tissue necrosis: A clinical challenge in neuro-oncology. Neuro Oncol 21 Verma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating Tumor Recurrence from Treatment Necrosis: A Review of Neuro-Oncologic Imaging Strategies. Neuro Oncol 15:515–534 Winter SF, Vaios EJ, Muzikansky A, Martinez-Lage M, Bussière MR, Shih HA, Loeffler J, Karschnia P, Loebel F, Vajkoczy P et al (2020) Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. Oncologist 25:e1221–e1232. 10.1634/theoncologist.2020-0085 Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J (2015) Standard Chemoradiation for Glioblastoma Results in Progressive Brain Volume Loss. Neurology 85:683–691. 10.1212/WNL.0000000000001861 Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J (2018) Standard Chemoradiation in Combination with VEGF Targeted Therapy for Glioblastoma Results in Progressive Gray and White Matter Volume Loss. Neuro Oncol 20:289–291 Akintola O, Dietrich J, Muzikansky A, Melissa G, Youssef G, Huang R, Gerstner E, Wen PY, Parsons M, Gilbert M et al (2022) NCOG-20. BRAIN ATROPHY IN GLIOBLASTOMA PATIENTS FOLLOWING TREATMENT WITH CHEMORADIATION OR CHEMORADIATION WITH ANTI-ANGIOGENIC THERAPY IN NRG/RTOG 0825 PARTICIPANTS. Neuro-Oncol 24:vii201. 10.1093/neuonc/noac209.773 Dietrich J, Monje M, Wefel J, Meyers C (2008) Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. Oncologist 13:1285–1295. 10.1634/theoncologist.2008-0130 Stone JB, DeAngelis LM (2016) Cancer-Treatment-Induced Neurotoxicity–Focus on Newer Treatments. Nat Rev Clin Oncol 13:92–105. 10.1038/nrclinonc.2015.152 Taphoorn MJ, Klein M (2004) Cognitive Deficits in Adult Patients with Brain Tumours. Lancet Neurol 3:159–168. 10.1016/S1474-4422(04)00680-5 Wilke C, Grosshans D, Duman J, Brown P, Li J (2018) Radiation-Induced Cognitive Toxicity: Pathophysiology and Interventions to Reduce Toxicity in Adults. Neuro Oncol 20:597–607 Kaiser J, Bledowski C, Dietrich J (2014) Neural Correlates of Chemotherapy-Related Cognitive Impairment. Cortex 54 , 10.1016/j.cortex.2014.01.010 Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J (1995) Biphasic Patterns of Memory Deficits Following Moderate-Dose Partial-Brain Irradiation: Neuropsychologic Outcome and Proposed Mechanisms. J Clin Oncol 13(9):2263–2271. 10.1200/JCO.1995.13.9.2263 Butler JM, Rapp S (2006) Managing the Cognitive Effects of Brain Tumor Radiation Therapy. Curr Treat Options Oncol. 10.1007/s11864-006-0026-5 Surma-aho O, Niemelä M, Vilkki J, Kouri M, Brander A, Salonen O, Paetau A, Kallio M, Pyykkönen J, Jääskeläinen J (2001) Adverse Long-Term Effects of Brain Radiotherapy in Adult Low-Grade Glioma Patients. Neurology 56:1285–1290. 10.1212/wnl.56.10.1285 Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN et al (2002) Effect of Radiotherapy and Other Treatment-Related Factors on Mid-Term to Long-Term Cognitive Sequelae in Low-Grade Gliomas: A Comparative Study. Lancet Lond Engl 360:1361–1368. 10.1016/s0140-6736(02)11398-5 Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH et al (2009) Cognitive and Radiological Effects of Radiotherapy in Patients with Low-Grade Glioma: Long-Term Follow-Up. Lancet Neurol 8:810–818. 10.1016/S1474-4422(09)70204-2 Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP et al (2021) Memory in Low-Grade Glioma Patients Treated with Radiotherapy or Temozolomide: A Correlative Analysis of EORTC Study 22033–26033. Neuro-Oncol 23:803–811. 10.1093/neuonc/noaa252 Kirman CR, North CM, Tretyakova NY, Erraguntla N, Shen H, Hays SM (2022) Use of Biomarker Data and Metabolite Relative Potencies to Support Derivation of Noncancer Reference Values Based on the Reproductive and Developmental Toxicity Effects of 1,3-Butadiene. Regul Toxicol Pharmacol 134:105239. 10.1016/j.yrtph.2022.105239 van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström P-O, Collette L, Piérart M, Mirimanoff R et al (2005) Long-Term Efficacy of Early versus Delayed Radiotherapy for Low-Grade Astrocytoma and Oligodendroglioma in Adults: The EORTC 22845 Randomised Trial. Lancet Lond Engl 366:985–990. 10.1016/S0140-6736(05)67070-5 Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, Nordman E, Silvestre ME, Pierart M, Karim AB (1998) Quality of Life after Radiation Therapy of Cerebral Low-Grade Gliomas of the Adult: Results of a Randomised Phase III Trial on Dose Response (EORTC Trial 22844). EORTC Radiotherapy Co-Operative Group. Eur J Cancer Oxf Engl 1990 34:1902–1909. 10.1016/s0959-8049(98)00268-8 Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB et al (2016) Temozolomide Chemotherapy versus Radiotherapy in High-Risk Low-Grade Glioma. Lancet Oncol 17:1521–1532. 10.1016/S1470-2045(16)30313-8 Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M et al (1996) A Randomized Trial on Dose-Response in Radiation Therapy of Low-Grade Cerebral Glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549–556. 10.1016/s0360-3016(96)00352-5 Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T et al (2002) Prospective Randomized Trial of Low- versus High-Dose Radiation Therapy in Adults with Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 20:2267–2276. 10.1200/JCO.2002.09.126 DeAngelis LM, Mandell LR, Thaler TH, Kimmel DW, Galicich JH, Fuks Z, Posner JB (1989) The Role of Postoperative Radiotherapy after Resection of Single Brain Metastases. Neurosurgery 24 Lisa M (1989) DeAngelis; Jean-Yves Delattre; Jerome B. Posner Radiation-induced Dementia in Patients Cured of Brain Metastases. Neurology 39:789. 10.1212/WNL.39.6.789 Newhauser WD, Zhang R (2015) The Physics of Proton Therapy. Phys Med Biol 60:155–209. 10.1088/0031-9155/60/8/R155 Jhaveri J, Cheng E, Tian S (2018) Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base. Front Oncol 8. 10.3389/fonc.2018.00440 Mohan R, Grosshans D (2017) Proton therapy - Present and future. Adv Drug Deliv Rev 109:26–44 Mohan R, Grosshans D (2017) Proton Therapy – Present and Future. Adv Drug Deliv Rev 109:26–44. 10.1016/j.addr.2016.11.006 Byskov CS, Hansen CR, Dahlrot RH, Haldbo-Classen L, Haslund CA, Kjær-Kristoffersen F, Kristensen TO, Lassen-Ramshad Y, Lukacova S, Muhic A et al (2021) Treatment Plan Comparison of Proton vs Photon Radiotherapy for Lower-Grade Gliomas. Phys Imaging Radiat Oncol 20:98–104. 10.1016/j.phro.2021.11.008 Harrabi SB, Nettelbladt B, Gudden C (2021) Radiation Induced Contrast Enhancement after Proton Beam Therapy in Patients with Low Grade Glioma – How Safe Are Protons? Radiother Oncol 167:211–218 Levin WP, Kooy H, Loeffler JS, DeLaney TF (2005) Proton Beam Therapy. Br J Cancer 93:849–854. 10.1038/sj.bjc.6602754 Shih HA, Sherman JC, Nachtigall LB (2015) Proton Therapy for Low-Grade Gliomas: Results from a Prospective Trial. Cancer 121:1712–1719 Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer M-F et al (2021) A Prospective Phase II Randomized Trial of Proton Radiotherapy vs Intensity-Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncol 23:1337–1347. 10.1093/neuonc/noab040 Sherman J, Colvin M, Mancuso S, Batchelor T, Oh K, Loeffler J, Shih H (2016) Neurocognitive Effects of Proton Radiation Therapy in Adults with Low-Grade Glioma. J Neurooncol 126:157–164. 10.1007/s11060-015-1952-5 World Medical Association World Medical Association Declaration of Helsinki (2013) Ethical Principles for Medical Research Involving Human Subjects. JAMA 310:2191–2194. 10.1001/jama.2013.281053 Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J (2018) Standard Chemoradiation in Combination with VEGF Targeted Therapy for Glioblastoma Results in Progressive Gray and White Matter Volume Loss. Neuro-Oncol 20:289–291. 10.1093/neuonc/nox217 Meyers CA, Brown PD (2006) Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors. J Clin Oncol 24:1305–1309. 10.1200/JCO.2005.04.6086 Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force Recommendations to Harmonise Studies of Cognitive Function in Patients with Cancer. Lancet Oncol 12:703–708. 10.1016/S1470-2045(10)70294-1 Durant J, Duff K, Miller JB (2019) Regression-Based Formulas for Predicting Change in Memory Test Scores in Healthy Older Adults: Comparing Use of Raw versus Standardized Scores. J Clin Exp Neuropsychol 41:460–468. 10.1080/13803395.2019.1571169 Evidence-Based Indicators of Neuropsychological Change in the Individual Patient: Relevant Concepts and Methods - Google Search Available online: https://www.google.com/search?q=Evidence-Based+Indicators+of+Neuropsychological+Change+in+the+Individual+Patient%3A+Relevant+Con cepts+and+Methods&rlz=1C5GCEM_enUS1069US1072&oq=Evidence- Based+Indicators+of+Neuropsychological+Change+in+the+Individual+Patient%3A+Relevant+Con cepts+and+Methods&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBBzQwNWowajSoAgCwAgA&sour ceid=chrome&ie=UTF-8 (accessed on 30 October 2023). Winter SF, Gardner MM, Karschnia P, Vaios EJ, Grassberger C, Brussiere MR, Nikolic K, Pongpitakmetha T, Ehret F, Kaul D, Boehmerle W, Endres M, Shih H, Parsons MW, Dietrich J (2024) Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2–3 gliomas. Oncologist oyae195. https://doi.org/10.1093/oncolo/oyae195 Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer M-F et al (2021) A Prospective Phase II Randomized Trial of Proton Radiotherapy vs Intensity-Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncol 23:1337–1347. 10.1093/neuonc/noab040 Wen PY, Kesari S (2008) Malignant Gliomas in Adults. N Engl J Med 359:492–507. 10.1056/NEJMra0708126 Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS et al (2023) Isocitrate Dehydrogenase (IDH) Mutant Gliomas: A Society for Neuro-Oncology (SNO) Consensus Review on Diagnosis, Management, and Future Directions. Neuro-Oncol 25:4–25. 10.1093/neuonc/noac207 Eekers DB, Zegers CM, Ahmed KA, Amelio D, Gupta T, Harrabi SB, Kazda T, Scartoni D, Seidel C, Shih HA, Minniti G (2024) Controversies in neuro-oncology: focal proton versus photon radiation therapy for adult brain tumors. Neuro-Oncology Practice, p npae040 Chen Z, Ye N, Teng C, Li X (2022) Alternations and Applications of the Structural and Functional Connectome in Gliomas: A Mini-Review. Front Neurosci 16:856808. 10.3389/fnins.2022.856808 Oncology NRG (2022) National Cancer Institute (NCI. In NCT03180502: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Additional Declarations Competing interest reported. Michael W. Parsons serves as a consultant to Servier Pharmaceuticals. Supplementary Files Gardner.SupplementaryTableS1.docx Cite Share Download PDF Status: Published Journal Publication published 14 Oct, 2024 Read the published version in Journal of Neuro-Oncology → Version 1 posted Editorial decision: Revision requested 15 Sep, 2024 Reviews received at journal 11 Sep, 2024 Reviewers agreed at journal 03 Sep, 2024 Reviewers agreed at journal 03 Sep, 2024 Reviewers agreed at journal 01 Sep, 2024 Reviewers invited by journal 31 Aug, 2024 Editor assigned by journal 31 Aug, 2024 Submission checks completed at journal 31 Aug, 2024 First submitted to journal 25 Aug, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4973431","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":354254589,"identity":"ba030bb8-e5e0-46ee-a323-645ea3cfcc51","order_by":0,"name":"Melissa M. Gardner","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Melissa","middleName":"M.","lastName":"Gardner","suffix":""},{"id":354254590,"identity":"23c86759-12cc-4ea3-aa62-139ca25eec9e","order_by":1,"name":"Sebastian F. Winter","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Sebastian","middleName":"F.","lastName":"Winter","suffix":""},{"id":354254591,"identity":"57250ffe-814b-4776-94cc-e82a08ad2232","order_by":2,"name":"Franziska Stahl","email":"","orcid":"","institution":"Schoen Clinic Munich Schwabing","correspondingAuthor":false,"prefix":"","firstName":"Franziska","middleName":"","lastName":"Stahl","suffix":""},{"id":354254592,"identity":"02dff56d-b27a-4f4d-b07e-4483adcde540","order_by":3,"name":"Elizabeth R. Gerstner","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Elizabeth","middleName":"R.","lastName":"Gerstner","suffix":""},{"id":354254593,"identity":"ce45fb4d-3e41-4b96-acd2-5994843b3d78","order_by":4,"name":"Helen A. Shih","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Helen","middleName":"A.","lastName":"Shih","suffix":""},{"id":354254594,"identity":"03ee2098-ee86-4ded-a9b0-a09c5aab2b8e","order_by":5,"name":"Janet Sherman","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Janet","middleName":"","lastName":"Sherman","suffix":""},{"id":354254595,"identity":"3da73d1f-dc6a-4945-a9a3-36f394d66a76","order_by":6,"name":"Jorg Dietrich","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Jorg","middleName":"","lastName":"Dietrich","suffix":""},{"id":354254596,"identity":"4e7f9551-b435-4729-94ab-e8951147cc3f","order_by":7,"name":"Michael W. Parsons","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABCUlEQVRIiWNgGAWjYFAD9gYGZgaGAxAODwMDYwNBLTwHSNYikUCkFt0ZuQc/V/yxyZOf+Tr5dQHDHXnzGcnPPrxhsJHdcAC7FrMbecmSZ9vSig1u526znsHwzHDOjTTjmXMY0oxxarmdYyDZ2HA4cYN07jZjHobDjDN4DhgzAxmJeLQY/2z4czhx/syzYC32M3iOfwZq+Y9Pi5lkA9vhxIYbvJsfgwyfwd4DsuUAbi3336VZNralJW44k7uNmcfgcDJQSzHjHINk45m4tJw5e/hmwx+bxPntZzd/5qk4bDuDmX0zw5sKO9k+HFrAUQAFbBIMBjC2AVa1GFqYP+BTNwpGwSgYBSMXAADiH2TxiLQqBQAAAABJRU5ErkJggg==","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":true,"prefix":"","firstName":"Michael","middleName":"W.","lastName":"Parsons","suffix":""}],"badges":[],"createdAt":"2024-08-25 15:40:45","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4973431/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4973431/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s11060-024-04850-9","type":"published","date":"2024-10-14T15:57:36+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":65707907,"identity":"1732792a-f153-4fa2-b41e-d796e6324773","added_by":"auto","created_at":"2024-10-01 13:53:09","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":309026,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eBaseline and follow-up MRI with volumetric extraction:\u003c/strong\u003e(a) Axial view of baseline MRI of patient with a right-frontal tumor/resection cavity and (b) two years later at the follow-up time point. Panel (c) shows a three-dimensional model of the lateral ventricle space extracted from the contralesional hemisphere and (d) shows the contralateral hemisphere and ventricular volume assessment from an axial-view in Slicer without the 3D extraction (labeled in green)\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4973431/v1/e06946ff056ac87e523e6a76.png"},{"id":65707589,"identity":"ce85bc36-53e7-4c9a-af9c-473b690fe041","added_by":"auto","created_at":"2024-10-01 13:45:09","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":48006,"visible":true,"origin":"","legend":"\u003cp\u003ePercent change in ventricular volume from baseline to follow-up\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4973431/v1/7c4c423e4f291ce5bcf7b2f7.png"},{"id":65707587,"identity":"0a3f3dc6-d097-4e3a-b58b-ee587ef66caa","added_by":"auto","created_at":"2024-10-01 13:45:09","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":95624,"visible":true,"origin":"","legend":"\u003cp\u003eCorrelations between change in ventricular volume and cognition over time (e.g., baseline to two years).\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-4973431/v1/759e91bcbaf2c3449c530035.png"},{"id":67149722,"identity":"25a5e977-e78b-4fc8-89f4-78de5c9478bc","added_by":"auto","created_at":"2024-10-21 16:13:48","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1700362,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4973431/v1/22cba4f4-13c6-442e-bfd6-6dd2ef2c3453.pdf"},{"id":65707905,"identity":"aaee307e-1267-4fa2-a7b2-f45d67aea22d","added_by":"auto","created_at":"2024-10-01 13:53:09","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":63478,"visible":true,"origin":"","legend":"","description":"","filename":"Gardner.SupplementaryTableS1.docx","url":"https://assets-eu.researchsquare.com/files/rs-4973431/v1/5349b5dc1ab4ed7097ed708e.docx"}],"financialInterests":"Competing interest reported. Michael W. Parsons serves as a consultant to Servier Pharmaceuticals.","formattedTitle":"Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eGliomas are infiltrative primary central nervous system (CNS) tumors that are classified by histologic and molecular criteria [\u003cspan additionalcitationids=\"CR2 CR3 CR4\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Treatment typically consists of maximal safe tumor resection followed by additional tumor directed treatments to slow progression and delay recurrence. Despite advances in cancer therapy to prolong patient survival, WHO grade 2\u0026ndash;4 glial tumors are considered incurable neoplasms [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. The treatment for many gliomas includes combined chemotherapy and radiation therapy (RT) [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. While such treatments have been shown to prolong survival, there are known neurotoxic sequelae of such treatments.\u003c/p\u003e \u003cp\u003eNeurotoxic effects following RT to the brain include cerebral volume loss [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e], injury to white matter [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e], vascular disruption [\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], and radiation necrosis [\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e], which can greatly impact an individual\u0026rsquo;s quality of life (QoL). Previous studies from our group have shown that patients with glioblastoma (GBM) who were treated with photon RT (XRT) combined with systemic chemotherapy experience progressive whole brain volume loss as well as grey matter volume loss and white matter integrity changes in the hemisphere contralateral to the tumor/radiation target, suggesting a diffuse neurotoxic effect of such therapy on the brain [\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Cerebral atrophy after RT appears to be irreversible and can contribute to cognitive dysfunction [\u003cspan additionalcitationids=\"CR24 CR25\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e] through a pattern of progressive cognitive decline [\u003cspan additionalcitationids=\"CR28\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Balancing the antineoplastic benefit of cancer directed therapy with these neurotoxic adverse effects is a challenge, given the ultimate goal to improve both quantity and quality of life in glioma survivors [\u003cspan additionalcitationids=\"CR6\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThere have been mixed outcomes in studies of neurotoxic effects of treatment in patients with lower grade gliomas (LGG) following radiation therapy (RT). While many studies have revealed cognitive deterioration after RT [\u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e], some studies have suggested that minimal to no decline occurred [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] or that confounding variables (e.g., tumor location or laterality) [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] influenced cognitive performance to a greater extent than treatment-related changes [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIndeed, variation in RT characteristics may influence neurotoxicity patterns and degree, including fraction size and total dose [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan additionalcitationids=\"CR38 CR39 CR40\" citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. Studies examining the type of RT used in patients with WHO grade 2\u0026ndash;3 glioma and the associated treatment-related sequalae over time are warranted.\u003c/p\u003e \u003cp\u003eThe dosimetric and radiobiological advantages of proton RT (PRT), as compared with photon RT (XRT), restrict radiation delivery to the target region, potentially sparing healthy brain tissue [\u003cspan additionalcitationids=\"CR43 CR44\" citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. The superior dose distribution of protons [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e, \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e] is due to a radiation beam that travels a finite length and disproportionately delivers much of its dose at the end its path, known as the Bragg Peak, placed in the intended target [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. In a prospective study, Brown et al. compared PRT to XRT in patients with GBM, seeking to determine whether PRT would prolong time to cognitive deterioration [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. The study found a substantial reduction in radiation dose to brain structures critical to cognitive outcome (e.g., left hippocampus) in the PRT group compared to the XRT cohort. Despite reduced radiation dose to healthy brain tissue in the PRT cohort, there was no difference in cognitive deterioration between groups. Because of the aggressive nature of GBM, the study had limited power due to the rapid deterioration and tumor progression seen in both groups. A prospective, longitudinal study examining cognitive function in adults with LGG receiving PRT showed no decline in cognitive performance at 5 years after treatment, suggesting the possibility of long-term cognitive stability after PRT, but without comparison to XRT treated individuals [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. Whether PRT may reduce diffuse neurotoxicity when compared to conventional XRT in patients with LGG remains an area of active investigation.\u003c/p\u003e \u003cp\u003eThe primary purpose of this study was to longitudinally explore treatment-induced structural and functional neurotoxic complications in adults with lower grade glioma (WHO grades 2\u0026ndash;3) following partial cranial radiation treatment. Specifically, we compared brain volume changes for up to two years following PRT vs XRT treatment in carefully matched patient cohorts. We hypothesized that PRT would be associated with less neurotoxicity than XRT, as assessed by brain volume loss contralateral to the glioma target. In addition, taking advantage of prospective longitudinal neuropsychological assessment that had been conducted in the cohort of PRT patients, we sought to explore the relationships between contralesional volumetric changes and cognitive performance over a two-year time period following treatment.\u003c/p\u003e"},{"header":"2. Materials and Methods","content":"\u003cp\u003eA secondary retrospective case-control study design was used to investigate demographic, clinical (e.g., treatment variables), and histopathological data in a total of 34 adult patients with lower grade glioma (WHO grades 2\u0026ndash;3) treated with either XRT or PRT at the Massachusetts General Hospital (MGH) between 11/1998\u0026ndash;10/2017. Patients treated with PRT were identified from ongoing longitudinal single-arm outcome studies at our institution (NCT01358058, NCT03286335), which included routine brain MRI and serial neuropsychological assessments. Patients treated with XRT were identified from an archival database from the Departments of Radiation Oncology and the Division of Neuro-Oncology at MGH. All PRT patients signed informed consent for participation in the outcome studies enumerated above. The XRT patient data was gathered under a Mass General Brigham IRB approved research protocol for secondary retrospective analyses of medical record data. All research procedures were conducted in accordance with the Declaration of Helsinki [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e] As indicated above, patients treated with XRT had not completed neuropsychological assessment as part of their routine care, so only PRT patients were included in the detailed cognitive analyses.\u003c/p\u003e \u003cp\u003eInclusion criteria for all patients were: (a) pathologically confirmed grade 2 or grade 3 glioma as defined by the World Health Organization (pathology records included the WHO classification criteria that were in place at the time of diagnosis and were re-classified to meet the 2021 classification based on available data), (b) tumor burden limited to one hemisphere (e.g., tumors did not cross midline to minimize brain volume changes associated with tumor growth or regression after treatment), (c) age 18 years or older, (d) partial cranial radiation therapy (PRT or XRT) delivered at MGH, (e) availability of contrast-enhanced axial brain magnetic resonance imaging scans (e.g., MPRAGE, BRAVO, or thick slice T1 weighted MRI) at baseline (within eight weeks after completion of radiation therapy) as well as at yearly intervals or more frequently (part of routine cancer surveillance screening), and (f) a minimum of two years progression free survival following RT.\u003c/p\u003e \u003cp\u003eTo limit sampling bias, XRT patients were closely matched to \u0026ldquo;case-control\u0026rdquo; PRT patients using a carefully developed eleven-tiered set of criteria: age, sex, tumor type, tumor location, laterality of tumor, isocitrate dehydrogenase (IDH) 1 mutation status, 1p/19q co-deletion status, concurrent chemotherapy, adjuvant chemotherapy, total radiation dose, and number of radiation fractions. Participants were first matched on an individual level, followed by a group match for patients (n\u0026thinsp;=\u0026thinsp;6) that did not match on all eleven variables.\u003c/p\u003e \u003cp\u003eStructural MRI scans were collected for patients at baseline, one year, and at two years after RT. When available, thin-slice (1mm) imaging (e.g., MPRAGE, BRAVO, and T1) was used for volume quantification; thick-slice (6mm) images were used for those cases without thin-slice imaging. As in our prior studies [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e], we measured volume change in the lateral ventricle in the hemisphere contralateral to the tumor as an index of diffuse cerebral volume loss. Ventricular segmentation was performed manually using Slicer (Version 4.10.2) to generate a 3D model of the contralesional ventricle, as illustrated in \u003cb\u003eFig.\u0026nbsp;1\u003c/b\u003e. The manual segmentation process was carried out by two trained research technicians following extensive training from board-certified neuro-oncologists (J.D. and E.G.) to ensure accurate identification of the limits of the ventricle. Each researcher identified the area of interest or ventricular space on a single axial slice using a \u0026ldquo;point and click\u0026rdquo; method to place a \u0026ldquo;seed\u0026rdquo; in the ventricular space and then used the \u0026ldquo;grow from seeds\u0026rdquo; function in Slicer to fill in all areas of the ventricle across slices. The program computed volume as the product of voxel size in the individual patient\u0026rsquo;s image space multiplied by the number of voxels labeled as included in the ventricle. Inter-rater reliability was evaluated by random selection of ventricular measurements for ten patients at each time point using the same method.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eINSERT FIGURE 1 HERE\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAs noted above, PRT patients completed neurocognitive assessment at baseline (e.g., after the surgical resection and before start of radiotherapy) and follow-up (e.g., two years after baseline). All neuropsychological evaluations were carried out by a neuropsychologist (J.S.) with testing assistance from a psychometrist. The detailed neuropsychological evaluation included cognitive screening measures, attention/working memory, processing speed, executive functioning, language, memory, and measures of depression and anxiety (See \u003cb\u003eSupplemental Table\u0026nbsp;1\u003c/b\u003e for complete list of tests). Embedded within the assessment was the \"clinical trial battery composite\u0026rdquo; (CBTC) which generates a composite score routinely used in large scale clinical trials of cognitive outcomes in patients with brain tumors [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. The CTBC is the mean of the Z-scores of the following six metrics: Controlled oral word association (COWA), Trail Making Test parts A and B (TMT-A and B), and total recall, delayed recall, and recognition discrimination scores from the Hopkins Verbal Learning Test-Revised (HVLT-R)[\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e] Normative data (e.g., conversion to z-scores using published test norms) for neuropsychological assessment allows for a standardized comparison of individual performance while controlling for demographic factors (e.g., age, education). In repeat or serial cognitive assessment, it is controversial whether discrete norms yield invalid or additional error [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e]; therefore, raw scores were used in analyses assessing change over time. Linear regression and correlation coefficients were calculated to examine the relationship between change in ventricular volumes and change in cognitive performance in patients treated with PRT. Non-parametric tests were used for binary variables indicating cognitive deterioration.\u003c/p\u003e \u003cp\u003eStatistical analyses were performed with the Statistical Package for the Social Sciences (SPSS-29). Descriptive statistics were calculated for demographic, diagnostic and treatment data for the two study groups (PRT and XRT) and compared with non-parametric analyses including the Mann-Whitney U-test of independence to evaluate their equivalence. Percent change in lateral ventricle volume between the two study groups was evaluated using a repeated-measures ANOVA with treatment as the between groups factor (XRT and PRT) and time (year 1 and 2 from baseline) as the within patients variable. Paired t-tests and simple linear regression analyses were used to test overall change from baseline to follow-up. Associations between lateral ventricle volume changes and measures of neurocognitive functioning, mood and anxiety were explored using correlations and linear regressions. To examine the relationship between ventricular volume and cognitive decline, the mean change in raw scores for each cognitive test was determined and those patients whose cognitive decline was 1 standard deviation or more below the mean change for the group were defined as \u0026ldquo;decliners\u0026rdquo; on that test. The number of cognitive tests showing a decline was tabulated for each individual and plotted into a simple linear regression. An alpha of .01 was used to control for multiple comparisons of the neurocognitive baseline and follow-up analyses and should be interpreted as exploratory.\u003c/p\u003e"},{"header":"3. Results","content":"\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e3.1. Demographics\u003c/h2\u003e \u003cp\u003eOver 80% (n\u0026thinsp;=\u0026thinsp;28/34) of patients were precisely matched at an individual level based on all eleven specified criteria. Six additional patients differed in no more than two of the eleven variables and were added to the total sample (shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Following this matching process, 34 patients with \u003cem\u003eprogression-free\u003c/em\u003e WHO grade 2 or 3 gliomas were included with 17 patients in each cohort (17 PRT matched with 17 XRT). As shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e, there were no statistically significant differences between groups on demographics, tumor characteristics or treatment variables. Review of clinically acquired brain imaging confirmed that patients remained free from tumor progression during the two-year study period.\u003c/p\u003e \u003cp\u003e \u003cb\u003eINSERT\u003c/b\u003e Table \u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e \u003cb\u003eHERE\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSummary of patient characteristics, treatment specifics, and clinical outcome.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePatient characteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eTotal cohort\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eXRT\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003ePRT\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003ep value for difference between groups\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNo of patients included\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDemographics\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% sex ratio (m/f)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e56 / 44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e59 / 41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e53 / 47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.119, p\u0026thinsp;=\u0026thinsp;0.730\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian Age at diagnosis (yrs)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e39.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003et=-0.115, p\u0026thinsp;=\u0026thinsp;0.126\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTumor specifics\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIntracranial Location\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;4.877, p\u0026thinsp;=\u0026thinsp;0.431\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% left / right\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e56 / 44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47 / 53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e65 / 35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;1.074, p\u0026thinsp;=\u0026thinsp;0.300\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% frontal (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50.0 (17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47.1 (8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e52.9 (9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% temporal (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32.4 (11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41.2 (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23.5 (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% insular (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.9 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.8 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% thalamic (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.9 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% parietal (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% cerebellopontine angle (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWHO Grade % (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.582, p\u0026thinsp;=\u0026thinsp;0.748\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e64.7 (22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58.8 (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e70.6 (12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29.4 (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.3 (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23.5 (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003elow grade, not otherwise specified\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.9 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHistopathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.183, p\u0026thinsp;=\u0026thinsp;0.913\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% astrocytoma* (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e73.5 (25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e76.5 (13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e70.6 (12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% oligodendroglioma (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20.6 (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17.6 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23.5 (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% low grade astrocytoma, not otherwise specified\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.9 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMolecular-genetic profile\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% IDH1 mutant (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e82.4 (28)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e76.5 (13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e88.2 (15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.81, p\u0026thinsp;=\u0026thinsp;0.368\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% 1p19q co-deleted (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37.0 (10/27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38.5 (5/13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e35.7 (5/14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.02, p\u0026thinsp;=\u0026thinsp;0.883\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% p53 mutated (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37.0 (10/27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e54.5 (6/11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e25.0 (4/16)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cb\u003eX\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;6.367, p\u0026thinsp;=\u0026thinsp;0.041\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% ATRX loss\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e42.1 (8/19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33.3 (2/6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e46.2 (6/13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cb\u003eX\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;6.085, p\u0026thinsp;=\u0026thinsp;0.048\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% MGMT promoter methylated (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50.0 (6/12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42.9 (3/7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e60.0 (3/5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;1.238, p\u0026thinsp;=\u0026thinsp;0.538\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClinical status\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% w/ cardiovascular comorbidities\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e61.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70.6 (12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e52.9 (9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;3.84, p\u0026thinsp;=\u0026thinsp;0.147\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% w/ recurrence prior to RT (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e35 (12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24 (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47 (8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;2.06, p\u0026thinsp;=\u0026thinsp;0.151\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian KPS baseline pre-RT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003et\u0026thinsp;=\u0026thinsp;1.343, p\u0026thinsp;=\u0026thinsp;0.165\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian KPS 2 years post-RT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003et=-0.026, p\u0026thinsp;=\u0026thinsp;0.475\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTreatment details\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExtent of surgical resection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;5.727, p\u0026thinsp;=\u0026thinsp;0.126\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% GTR (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.8 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.8 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% NTR (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e17.6 (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e35.3 (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% STR (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32.4 (11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.4 (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e35.3 (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% PR (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e17.6 (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17.6 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17.6 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% Biopsy only (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23.5 (8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41.2 (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.9 (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cb\u003eX\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;5.1, p\u0026thinsp;=\u0026thinsp;0.024\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRadiotherapy Regimen\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003en/a\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% Photons (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50 (17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100 (17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN/A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% IMRT (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.4 (5/17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN/A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% VMAT (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17.7 (3/17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN/A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% 3D CRT (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.9 (1/17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN/A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% IFRT, not otherwise specified\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47.1 (8/17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% Protons (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50 (17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eN/A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100 (17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian Dose in Gy (range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e54 (9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e59.4 (9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e54(RBE) (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003et\u0026thinsp;=\u0026thinsp;1.92, p\u0026thinsp;=\u0026thinsp;0.065\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian No. Fractions (range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e30 (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33 (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003et\u0026thinsp;=\u0026thinsp;1.41, p\u0026thinsp;=\u0026thinsp;0.167\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian Fraction size in Gy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.8(RBE)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003et\u0026thinsp;=\u0026thinsp;1.00, p\u0026thinsp;=\u0026thinsp;0.325\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSystemic Treatment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% w/ neoadjuvant Ctx (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14.7 (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17.6 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.8 (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;5.034, p\u0026thinsp;=\u0026thinsp;0.412\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% w/ concurrent Ctx (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32.4 (11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.5 (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29.4 (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.134, p\u0026thinsp;=\u0026thinsp;.714\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% w/ adjuvant Ctx (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e67.6 (23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58.8 (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e76.5 (13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;1.209, p\u0026thinsp;=\u0026thinsp;0.271\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClinical outcome\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian PFS post-RT in years (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.0 (3.69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.7 (4.95)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.1 (1.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003ep\u0026thinsp;=\u0026thinsp;.134, CI-5.52 -8.3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% w/ recurrence post-RT (N)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e44.1 (15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58.8 (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29.4 (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e\u003cem\u003eX\u003c/em\u003e\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;2.43, p\u0026thinsp;=\u0026thinsp;0.119\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003eAbbreviations: ATRX\u0026thinsp;=\u0026thinsp;alpha-thalassemia/mental retardation, X-linked; Ctx\u0026thinsp;=\u0026thinsp;chemotherapy; f\u0026thinsp;=\u0026thinsp;female; GTR\u0026thinsp;=\u0026thinsp;gross total resection; IDH1\u0026thinsp;=\u0026thinsp;isocitrate dehydrogenase 1; IFRT\u0026thinsp;=\u0026thinsp;involved-field radiation therapy; IMRT= intensity-modulated radiation therapy; KPS\u0026thinsp;=\u0026thinsp;Karnofsky Performance Satus Scale; m\u0026thinsp;=\u0026thinsp;male; MGMT\u0026thinsp;=\u0026thinsp;Methylguanine methyltransferase; NTR\u0026thinsp;=\u0026thinsp;near total resection; PFS\u0026thinsp;=\u0026thinsp;progression-free survival; PR\u0026thinsp;=\u0026thinsp;partial resection; RT\u0026thinsp;=\u0026thinsp;radiotherapy; SD\u0026thinsp;=\u0026thinsp;standard deviation; STR\u0026thinsp;=\u0026thinsp;subtotal resection; VMAT\u0026thinsp;=\u0026thinsp;volumetric modulated arc therapy; WHO\u0026thinsp;=\u0026thinsp;World Health Organization; yrs\u0026thinsp;=\u0026thinsp;years\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e*The majority (n\u0026thinsp;=\u0026thinsp;21) of tumors were classified as \u0026ldquo;Astrocytoma, IDH mutant\u0026rdquo; as per WHO 2021 classification. In the remainder (n\u0026thinsp;=\u0026thinsp;4), imaging, histopathology, and disease course were consistent with grade 2/3 astrocytoma although detailed molecular information were not available given the retrospective nature of the study.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e reproduced with permission from Winter et al., 2024 [58]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e3.2. Volumetric Analysis\u003c/h2\u003e \u003cp\u003eThe preferred brain MRI sequence for measurement of ventricular volume is a 3-dimensional high resolution T1-weighted image with 1mm slice thickness (e.g., MPRAGE, BRAVO). However, this sequence was not always obtained in standard clinical brain MRI studies between 1998 and 2017. Although the PRT cohort had high resolution T1-weighted images with 1mm slices available for all 17 patients at both time points (i.e., baseline and follow-up), seven XRT patients did not have high resolution imaging available at both time points. Ventricular volumes for these seven XRT patients were measured using T1-weighted images with 6 mm slice thickness. The Shapiro-Wilk tests revealed the raw volumetric MRI data at baseline (p\u0026thinsp;=\u0026thinsp;0.069 and 0.046) was normally distributed. However, the difference between ventricular volume measurements in those with 1mm MRI slices vs 6mm MRI slices was statistically significant (F([\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]\u0026thinsp;=\u0026thinsp;6.66, p\u0026thinsp;=\u0026thinsp;.015).\u003c/p\u003e \u003cp\u003eTo control for the systematic difference in raw volumes between different imaging types, we used the same image type (e.g., thick slice images) at both the baseline and follow up time points for the 7 patients who did not have thin slice imaging available at one of those points. For subsequent analyses, we calculated the percent change in ventricular volume for each patient using images with identical geometry at baseline and two-year follow up (ventricular volume at two years minus ventricular volume at baseline divided by ventricular volume at baseline * 100). An ANOVA showed no significant difference between image types (thick vs thin slice) using percent volume change at one year (F[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]\u0026thinsp;=\u0026thinsp;0.077, p\u0026thinsp;=\u0026thinsp;.783) as the dependent variable, with a normal distribution and no outliers. Ventricular volume calculations using high resolution (thin slab) images were highly reliable, with intra-class correlations coefficients (ICC) showing excellent agreement between raters at baseline (ICC\u0026thinsp;=\u0026thinsp;.969) and follow-up (ICC\u0026thinsp;=\u0026thinsp;.931).\u003c/p\u003e \u003cp\u003eA repeated-measures ANOVA found a main effect of time, whereby overall ventricular volume was significantly greater (F(1, 31)\u0026thinsp;=\u0026thinsp;18.45, p\u0026thinsp;=\u0026thinsp;\u0026lt;\u0026thinsp;.000, partial η2\u0026thinsp;=\u0026thinsp;.373) in all patients after two years. There was also a main effect of treatment type; the XRT group had greater percent change in volume of the contralesional lateral ventricle (M\u0026thinsp;=\u0026thinsp;26.55%, SD\u0026thinsp;=\u0026thinsp;13.46%) than the PRT group (M\u0026thinsp;=\u0026thinsp;12.03%, SD\u0026thinsp;=\u0026thinsp;16.26; F(1,31)\u0026thinsp;=\u0026thinsp;4.26, p\u0026thinsp;=\u0026thinsp;0.048, partial η2\u0026thinsp;=\u0026thinsp;0.121). A statistically significant interaction effect (1,31)\u0026thinsp;=\u0026thinsp;10.16, p\u0026thinsp;=\u0026thinsp;0.003 partial η2\u0026thinsp;=\u0026thinsp;.247 was found between PRT and XRT over time, where patients treated with photons showed greater change at 2 years, as shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cb\u003eINSERT\u003c/b\u003e FIGURE \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u003cb\u003eHERE\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e3.3. Neurocognitive, emotional, and behavioral assessment\u003c/h2\u003e \u003cp\u003eExploratory analyses were conducted to examine changes in neuropsychological performance over time (i.e., from baseline to follow-up) for 16 of the 17 patients in the PRT group (one patient did not undergo cognitive testing). Descriptive statistics are presented in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cb\u003eINSERT\u003c/b\u003e Table \u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u003cb\u003eHERE\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNeurocognitive domains and tests scores for exploratory analyses\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBaseline\u003c/p\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFollow-up\u003c/p\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCognitive Δ\u003c/p\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCorrelation with Δ Volume (r, p)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCognitive Domain\u003c/b\u003e\u003c/p\u003e \u003cp\u003eCognitive test(s)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCognitive Screen\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMMSE\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29.19 (1.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.19 (1.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.06 (1.53)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.459, p\u0026thinsp;=\u0026thinsp;0.073)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eACE-R\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e93.63 (6.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e93.63 (6.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.69 (4.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.793\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026lt;\u0026thinsp;0.001)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLanguage\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBoston Naming Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55.5 (4.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55.5 (4.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.13 (2.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.606\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;0.013)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAuditory Naming Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e49.25 (1.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e49.25 (1.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.25 (1.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.316, p\u0026thinsp;=\u0026thinsp;0.234)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSemantic Fluency: Animal Naming\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e22.19 (6.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22.19 (6.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.38 (4.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.308, p\u0026thinsp;=\u0026thinsp;0.246)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAttention | Working Memory\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWAIS-IV ; Digit Span\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27.13 (6.12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27.13 (6.12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1.13 (3.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.609\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;0.012)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWMS-III Spatial Span\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16.25 (3.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16.25 (3.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.44 (2.87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.328, p\u0026thinsp;=\u0026thinsp;0.215)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAuditory Consonant Trigrams\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34.75 (6.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.38 (8.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.37 (5.84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(t\u0026thinsp;=\u0026thinsp;1.626, p\u0026thinsp;=\u0026thinsp;0.125)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExecutive Function | Processing speed\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWAIS-IV; Coding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e70.5 (20.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70.5 (20.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.38 (9.97)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.704\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;0.002)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrail Making Test; Part A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26.81 (9.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26.81 (9.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.06 (6.65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;0.258, p\u0026thinsp;=\u0026thinsp;0.335)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrail Making Test; Part B\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e59.63 (26.15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e59.63 (26.15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.25 (19.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;0.473, p\u0026thinsp;=\u0026thinsp;0.064)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eControlled Oral Word Association Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43.75 (12.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43.75 (12.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.13 (7.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.06, p\u0026thinsp;=\u0026thinsp;0.826)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVerbal Memory\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHVLT-R Total Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24.56 (5.45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24.56 (5.45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.06 (6.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.48, p\u0026thinsp;=\u0026thinsp;0.06)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHVLT-R Delayed Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.06 (2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.06 (2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.06 (4.19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.433, p\u0026thinsp;=\u0026thinsp;0.094)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHVLT-R Recognition Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10.81 (1.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10.81 (1.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.13 (1.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.479, p\u0026thinsp;=\u0026thinsp;0.061)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVisual Memory\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24.11 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.06 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-3.40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBVMT-R Total Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23.56 (6.89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.56 (6.89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.44 (5.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.447, p\u0026thinsp;=\u0026thinsp;0.082)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBVMT-R Delayed Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.81 (2.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.81 (2.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.38 (2.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(r=-.549, p\u0026thinsp;=\u0026thinsp;0.027)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBVMT-R Recognition Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.81 (0.75)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.81 (0.75)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.13 (0.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(r=-.596, p\u0026thinsp;=\u0026thinsp;0.015)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClinical Trial Battery Composite Score \u0026dagger;\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e-0.18 (0.84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-0.19 (0.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.01 (0.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.47, p\u0026thinsp;=\u0026thinsp;0.066)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEmotional \u0026amp; Behavioral Functioning\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBeck Anxiety Inventory\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.63 (3.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.63 (3.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1 (4.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;.325, p\u0026thinsp;=\u0026thinsp;0.219)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBeck Depression Inventory\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.13 (6.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.13 (6.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.69 (3.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;0.163, p\u0026thinsp;=\u0026thinsp;0.546)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eAbbreviations (PRT cohort only): MMSE\u0026thinsp;=\u0026thinsp;Mini Mental State Examination; ACE-R\u0026thinsp;=\u0026thinsp;Addenbrooke's Cognitive Examination - Revised; WAIS-IV\u0026thinsp;=\u0026thinsp;Wechsler Adult Intelligence Scale \u0026minus;\u0026thinsp;4th edition; WMSIII\u0026thinsp;=\u0026thinsp;Wechsler Memory Scale\u0026mdash;3rd edition; ACT\u0026thinsp;=\u0026thinsp;Auditory Consonant Trigrams; HVLT-R\u0026thinsp;=\u0026thinsp;Hopkins Verbal Learning Test \u0026ndash; Revised; BVMT-R\u0026thinsp;=\u0026thinsp;Brief Visuospatial Memory Test \u0026ndash; Revised; Change\u0026thinsp;=\u0026thinsp;Δ\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStatistically significant (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003e\u0026dagger;Standardized z scores\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eContralesional ventricular volume and baseline neurocognitive scores did not significantly correlate prior to the start of treatment. Paired t-tests showed that there was no statistically significant change between baseline and follow-up on any of the neurocognitive assessment measures at the \u003cem\u003egroup level\u003c/em\u003e. However, at an \u003cem\u003eindividual level\u003c/em\u003e significant associations were observed between ventricular volume increases and declines on several cognitive test scores. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e3\u003c/span\u003e, volume change was moderately to strongly inversely associated with changes in ACE-R (r\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;.793, p\u0026thinsp;=\u0026thinsp;\u0026lt;\u0026thinsp;0.001), digit span (r\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;.609, p\u0026thinsp;=\u0026thinsp;0.012), coding (r\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;.704, p\u0026thinsp;=\u0026thinsp;0.002), naming (r\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;.606, p\u0026thinsp;=\u0026thinsp;0.013), visual memory delayed recall (r\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;.549, p\u0026thinsp;=\u0026thinsp;0.027) and visual recognition discrimination index (r\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;.596, p\u0026thinsp;=\u0026thinsp;0.015). Increase in ventricular volume showed a moderate negative correlation approaching statistical significance with the CTBC Z-score (r = -0.470; p\u0026thinsp;=\u0026thinsp;0.066). Emotional and behavioral functioning tests did not show a significant relationship with volumetric change at any time point (baseline or follow-up).\u003c/p\u003e \u003cp\u003e \u003cb\u003eINSERT\u003c/b\u003e FIGURE \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e3\u003c/span\u003e \u003cb\u003eHERE\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eVentricular enlargement also demonstrated sensitivity to the number of tests on which an individual showed cognitive decline (defined as a decline of greater than 1 SD more than the group mean change). Linear regression indicated that ventricular enlargement accounted for 60.3% of the variation in cognitive deterioration (F(1,14)\u0026thinsp;=\u0026thinsp;21.3, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) from baseline to follow-up. The strongest relationships between volume loss and cognitive deterioration were seen on the coding and digit span tests (partial r\u0026rsquo;s = -0.70 and \u0026minus;\u0026thinsp;.61, respectively; p\u0026rsquo;s\u0026thinsp;\u0026lt;\u0026thinsp;0.01; see Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cb\u003eINSERT\u003c/b\u003e Table \u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e \u003cb\u003eHERE\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNeurocognitive domains and tests scores for exploratory analyses\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBaseline\u003c/p\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFollow-up\u003c/p\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCognitive Δ\u003c/p\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCorrelation with Δ Volume (r, p)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCognitive Domain\u003c/b\u003e\u003c/p\u003e \u003cp\u003eCognitive test(s)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCognitive Screen\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMMSE\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29.19 (1.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.19 (1.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.06 (1.53)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.459, p\u0026thinsp;=\u0026thinsp;0.073)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eACE-R\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e93.63 (6.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e93.63 (6.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.69 (4.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.793\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026lt;\u0026thinsp;0.001)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLanguage\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBoston Naming Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55.5 (4.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55.5 (4.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.13 (2.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.606\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;0.013)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAuditory Naming Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e49.25 (1.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e49.25 (1.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.25 (1.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.316, p\u0026thinsp;=\u0026thinsp;0.234)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSemantic Fluency: Animal Naming\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e22.19 (6.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22.19 (6.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.38 (4.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.308, p\u0026thinsp;=\u0026thinsp;0.246)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAttention | Working Memory\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWAIS-IV ; Digit Span\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27.13 (6.12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27.13 (6.12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1.13 (3.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.609\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;0.012)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWMS-III Spatial Span\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16.25 (3.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16.25 (3.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.44 (2.87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.328, p\u0026thinsp;=\u0026thinsp;0.215)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAuditory Consonant Trigrams\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34.75 (6.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.38 (8.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.37 (5.84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(t\u0026thinsp;=\u0026thinsp;1.626, p\u0026thinsp;=\u0026thinsp;0.125)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExecutive Function | Processing speed\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWAIS-IV; Coding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e70.5 (20.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70.5 (20.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.38 (9.97)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(\u003c/b\u003e\u003cb\u003er\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;\u0026minus;\u0026thinsp;.704\u003c/b\u003e, \u003cb\u003ep\u003c/b\u003e\u0026thinsp;\u003cb\u003e=\u0026thinsp;0.002)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrail Making Test; Part A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26.81 (9.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26.81 (9.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.06 (6.65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;0.258, p\u0026thinsp;=\u0026thinsp;0.335)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrail Making Test; Part B\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e59.63 (26.15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e59.63 (26.15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.25 (19.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;0.473, p\u0026thinsp;=\u0026thinsp;0.064)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eControlled Oral Word Association Test\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43.75 (12.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43.75 (12.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.13 (7.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.06, p\u0026thinsp;=\u0026thinsp;0.826)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVerbal Memory\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHVLT-R Total Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24.56 (5.45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24.56 (5.45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.06 (6.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.48, p\u0026thinsp;=\u0026thinsp;0.06)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHVLT-R Delayed Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.06 (2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.06 (2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.06 (4.19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.433, p\u0026thinsp;=\u0026thinsp;0.094)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHVLT-R Recognition Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10.81 (1.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10.81 (1.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.13 (1.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.479, p\u0026thinsp;=\u0026thinsp;0.061)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVisual Memory\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24.11 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.06 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-3.40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBVMT-R Total Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23.56 (6.89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.56 (6.89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.44 (5.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.447, p\u0026thinsp;=\u0026thinsp;0.082)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBVMT-R Delayed Recall\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.81 (2.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.81 (2.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.38 (2.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(r=-.549, p\u0026thinsp;=\u0026thinsp;0.027)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBVMT-R Recognition Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.81 (0.75)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.81 (0.75)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.13 (0.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e(r=-.596, p\u0026thinsp;=\u0026thinsp;0.015)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClinical Trial Battery Composite Score \u0026dagger;\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e-0.18 (0.84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-0.19 (0.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.01 (0.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r=-0.47, p\u0026thinsp;=\u0026thinsp;0.066)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEmotional \u0026amp; Behavioral Functioning\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBeck Anxiety Inventory\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.63 (3.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.63 (3.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-1 (4.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;.325, p\u0026thinsp;=\u0026thinsp;0.219)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBeck Depression Inventory\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.13 (6.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.13 (6.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.69 (3.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e(r\u0026thinsp;=\u0026thinsp;0.163, p\u0026thinsp;=\u0026thinsp;0.546)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eAbbreviations (PRT cohort only): MMSE\u0026thinsp;=\u0026thinsp;Mini Mental State Examination; ACE-R\u0026thinsp;=\u0026thinsp;Addenbrooke's Cognitive Examination - Revised; WAIS-IV\u0026thinsp;=\u0026thinsp;Wechsler Adult Intelligence Scale \u0026minus;\u0026thinsp;4th edition; WMSIII\u0026thinsp;=\u0026thinsp;Wechsler Memory Scale\u0026mdash;3rd edition; ACT\u0026thinsp;=\u0026thinsp;Auditory Consonant Trigrams; HVLT-R\u0026thinsp;=\u0026thinsp;Hopkins Verbal Learning Test \u0026ndash; Revised; BVMT-R\u0026thinsp;=\u0026thinsp;Brief Visuospatial Memory Test \u0026ndash; Revised; Change\u0026thinsp;=\u0026thinsp;Δ\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStatistically significant (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cem\u003e\u0026dagger;Standardized z scores\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eTo our knowledge, the current study represents the first controlled comparison of PRT and XRT effects on brain volume and associated cognitive change over two years in patients with LGG. This study found that both PRT and XRT treatment for LGG were associated with substantial and progressive ventricular volume expansion over two years following treatment. This change was significantly greater in patients treated with XRT, with a mean percent change in lateral ventricular volume expansion contralateral to the tumor of 26.55% compared to 12.03% in the PRT group. Exploratory analyses examining correlations between ventricular volume change and cognition over time showed significant relationships on tests of global cognitive function, attention, working memory, processing speed, language, and visual memory. Measures of working memory and processing speed were strongly associated with volume change, whereas changes on a commonly used verbal memory measure, the HVLT-R, were not associated with volumetric change. This finding is of particular interest given the CTBC score includes measures from the HVLT-R but not from coding and digit span. Thus, studies limited to only the CTBC measures may be missing diffuse changes that impact attention/working memory and processing speed. Further dissection of simple attention (digit span forward) vs. working memory (digit span backward/sequencing) is warranted.\u003c/p\u003e \u003cp\u003eThe progressive brain volume loss in LGG patients treated with RT identified in this study supports previous findings from studies in GBM patients, which have demonstrated progressive brain volume loss following combined XRT and chemotherapy [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Our findings are also consistent with a study conducted by Petr et al. (2017), examining brain volume loss and cerebral perfusion patterns in patients with GBM treated with either XRT or PRT. However, in the Petr et al. (2017) study, significant cerebral atrophy was seen only in the non-tumor hemisphere of patients treated with XRT but not in patients treated with PRT [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. The location of high and low dose regions across conditions (PRT and XRT) predicted regional volume loss, although the authors identified that patient age was a confounding variable contributing to this finding. The careful age-match in our study suggests that greater ventricular volume increase is likely related to XRT treatment rather than age. Furthermore, in a concurrent study using this sample of patients, we have demonstrated unique patterns of white matter damage associated with each radiation modality, with increased evolution of diffuse leukoencephalopathy and cerebral microbleeds in the contralesional hemisphere in XRT as compared with PRT treated patients [\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e]. It is likely that both white and grey matter changes are contributing to the overall cerebral volume loss and ventricular expansion demonstrated here.\u003c/p\u003e \u003cp\u003eFew studies have integrated cognitive outcomes in the examination of radiation-associated neurotoxicity. A recent phase II trial did not find a difference in cognitive failure rates following proton compared to photon therapy 6 months after treatment in patients with glioblastoma (GBM) when assessed at a group level [\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e]. Despite the limited follow period (6 months), a significant difference in patient reported fatigue was observed, favoring the PRT (24%) over XRT (58%) arm. Our study suggests that the effects of treatment may become more apparent over time in progression free survivors of lower grade gliomas, with relative reduction of neurotoxic sequelae in those treated with PRT.\u003c/p\u003e \u003cp\u003eGiven the significant ventricular enlargement in the XRT group two years after treatment, analysis of the associated changes in cognitive functioning is a critical consideration. It is important to highlight that there was substantial variability in lateral ventricular volume changes over 2 years in both the PRT and XRT cohort. Our findings suggest that individuals who experience a higher degree of brain volume loss are more likely to have cognitive deterioration. Given the relationship between volume change and cognition, further examination of risk factors for lateral ventricular volume increase/brain volume loss in people undergoing RT is needed. Neurotoxicity of treatment is an important factor to consider in optimizing long term outcomes. RT has been a core component of treatment for patients with LGG for many years [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e], yet the treatment landscape is evolving [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e] and the value of PRT over XRT-based therapies is actively being investigated in the context of their relative risks and costs [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e]. Observing a cohort of patients with less aggressive gliomas (i.e., grade 2\u0026ndash;3, IDH-mutant), putatively less toxic treatment (e.g., IDH inhibitor therapy or temozolomide without radiation therapy) or favorable demographic variables (e.g., age, cognitive reserve, cardiovascular risk factors) would provide additional data on the effects of brain volume loss on a population with expected prolonged overall survival rates. It is also important to evaluate if changes in ventricle volume and the associated changes in cognitive functioning generalize across conditions (e.g., at different timepoints as well as domain specific cognitive change and at what timepoint).\u003c/p\u003e \u003cp\u003eLimitations of our study include its retrospective design, relatively small sample size, and the fact that cognitive assessment was available only for the PRT group. Consideration for tumor laterality and its relationship with cognitive performance or additional treatment related variables (e.g., extent of surgical history at baseline) would be beneficial. Future designs would benefit from securing uniform imaging and comparing the absolute volumetric change between groups. Integration of more advanced imaging, such as diffusion tensor imaging to evaluate white matter integrity and resting state functional MRI to measure functional connectivity, would further elucidate the underlying mechanisms of these brain changes [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e]. Additionally, extending volumetric surveillance past two years would inform researchers and healthcare providers about the long-term implications and progressive pattern of treatment related neurotoxicity. A randomized controlled trial is considered the gold standard for comparing two groups when evaluating the effectiveness and impact of treatment interventions as it offers the most rigorous method for hypothesis testing. While randomization was not feasible in this study, it is important to note that a randomized controlled trial is not always achievable as the treating physicians ethically must maintain clinical equipoise in addition to following known treatment standards. The ongoing cooperative group NRG Oncology BN005 study addresses this concern by randomizing IDH-mutant LGG patients between photon and proton therapy [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e] and includes cognitive assessment measures, which may provide further opportunity to study these issues.\u003c/p\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003eUnderstanding the pattern of progressive neural injury following RT is a critical step to develop future neuroprotective strategies and to ultimately improve QoL and survivorship in patients with glioma. This retrospective case-matched study identified that ventricular volume in patients with WHO grade 2\u0026ndash;3 gliomas receiving radiation therapy increased over two years following treatment. Patients treated with XRT had significantly greater change over time than those treated with PRT. The secondary analyses suggest that volume change correlated significantly with cognitive deterioration in the PRT group. Prospective studies are warranted to validate these findings in larger cohorts and understand the long-term impacts of different radiation modalities on brain structure and function.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research received no external funding.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interest Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMichael W. Parsons serves as a consultant to Servier Pharmaceuticals.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contribution Statement:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors contributed to the study conception and design, and results interpretation. Material preparation, data collection and analysis were performed by Melissa M. Gardner, Sebastian F. Winter, Franziska Stahl and Michael W. Parsons. The first draft of the manuscript was written by Melissa M. Gardner and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eResearch data for this work are available upon request to the corresponding author by any qualified investigator.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics Approval\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was performed in line with the principles of the Declaration of Helsinki. All research procedures were conducted with the approval of the Institutional Review Board of Mass General Brigham.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003e\u003cspan\u003eLouis DN, Perry A, Burger P (2014) International Society Of Neuropathology\u0026ndash;Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. Brain Pathol 24:429\u0026ndash;435\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eLouis DN, Ohgaki H, Wiestler OD (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97\u0026ndash;109\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eOstrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u0026ndash;2017. Neuro-Oncol 22:1\u0026ndash;96. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noaa200\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eOstrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012\u0026ndash;2016. Neuro-Oncol 21:1\u0026ndash;100. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noz150\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eLouis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro-Oncol 23:1231\u0026ndash;1251. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noab106\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eTaphoorn MJB, Sizoo EM, Bottomley A (2010) Review on Quality of Life Issues in Patients with Primary Brain Tumors. Oncologist 15:618\u0026ndash;626. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1634/theoncologist.2009-0291\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eBoele FW, Klein M, Reijneveld JC, Verdonck-de Leeuw IM, Heimans JJ (2014) Symptom Management and Quality of Life in Glioma Patients. CNS Oncol 3:37\u0026ndash;47. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2217/cns.13.65\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eStupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u0026ndash;996. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa043330\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eStupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. Lancet Oncol 10:459\u0026ndash;466. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1470-2045(09)70025-7\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003ePrust M (2015) Standard Chemoradiation for Glioblastoma Results in Progressive Brain Volume Loss. Harvard University\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003ePetr J, Platzek I, Hofheinz F (2018) Photon vs. Proton Radiochemotherapy: Effects on Brain Tissue Volume and Perfusion. Radiother Oncol 128:121\u0026ndash;127\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eRauch PJ, Park HS, Knisely JPS, Chiang VL, Vortmeyer AO (2012) Delayed Radiation-Induced Vasculitic Leukoencephalopathy. Int J Radiat Oncol 83:369\u0026ndash;375\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eTerziev R, Psimaras D, Marie Y, Feuvret L, Berzero G, Jacob J, Dehais C, Bompaire F, Mueller W, Kinnersley B et al (2021) Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. Sci Rep 11:10176. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-021-89216-1\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWinter SF, Klein JP, Vaios EJ (2021) Clinical Presentation and Management of SMART Syndrome. Neurology 97:118\u0026ndash;120\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eAizer AA, Du R, Wen PY, Arvold ND (2015) Radiotherapy and Death from Cerebrovascular Disease in Patients with Primary Brain Tumors. J Neurooncol 124:291\u0026ndash;297\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eRoongpiboonsopit D, Kuijf HJ, Charidimou A (2017) Evolution of Cerebral Microbleeds after Cranial Irradiation in Medulloblastoma Patients. Neurology 88:789\u0026ndash;796\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWinter SF, Loebel F, Loeffler J (2019) Treatment-induced brain tissue necrosis: A clinical challenge in neuro-oncology. Neuro Oncol \u003cem\u003e21\u003c/em\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eVerma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating Tumor Recurrence from Treatment Necrosis: A Review of Neuro-Oncologic Imaging Strategies. Neuro Oncol 15:515\u0026ndash;534\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWinter SF, Vaios EJ, Muzikansky A, Martinez-Lage M, Bussi\u0026egrave;re MR, Shih HA, Loeffler J, Karschnia P, Loebel F, Vajkoczy P et al (2020) Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. Oncologist 25:e1221\u0026ndash;e1232. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1634/theoncologist.2020-0085\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003ePrust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J (2015) Standard Chemoradiation for Glioblastoma Results in Progressive Brain Volume Loss. Neurology 85:683\u0026ndash;691. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1212/WNL.0000000000001861\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003ePrust ML, Jafari-Khouzani K, Kalpathy-Cramer J (2018) Standard Chemoradiation in Combination with VEGF Targeted Therapy for Glioblastoma Results in Progressive Gray and White Matter Volume Loss. Neuro Oncol 20:289\u0026ndash;291\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eAkintola O, Dietrich J, Muzikansky A, Melissa G, Youssef G, Huang R, Gerstner E, Wen PY, Parsons M, Gilbert M et al (2022) NCOG-20. BRAIN ATROPHY IN GLIOBLASTOMA PATIENTS FOLLOWING TREATMENT WITH CHEMORADIATION OR CHEMORADIATION WITH ANTI-ANGIOGENIC THERAPY IN NRG/RTOG 0825 PARTICIPANTS. Neuro-Oncol 24:vii201. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noac209.773\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eDietrich J, Monje M, Wefel J, Meyers C (2008) Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. Oncologist 13:1285\u0026ndash;1295. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1634/theoncologist.2008-0130\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eStone JB, DeAngelis LM (2016) Cancer-Treatment-Induced Neurotoxicity\u0026ndash;Focus on Newer Treatments. Nat Rev Clin Oncol 13:92\u0026ndash;105. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrclinonc.2015.152\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eTaphoorn MJ, Klein M (2004) Cognitive Deficits in Adult Patients with Brain Tumours. Lancet Neurol 3:159\u0026ndash;168. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1474-4422(04)00680-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWilke C, Grosshans D, Duman J, Brown P, Li J (2018) Radiation-Induced Cognitive Toxicity: Pathophysiology and Interventions to Reduce Toxicity in Adults. Neuro Oncol 20:597\u0026ndash;607\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eKaiser J, Bledowski C, Dietrich J (2014) Neural Correlates of Chemotherapy-Related Cognitive Impairment. \u003cem\u003eCortex 54\u003c/em\u003e, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cortex.2014.01.010\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eArmstrong C, Ruffer J, Corn B, DeVries K, Mollman J (1995) Biphasic Patterns of Memory Deficits Following Moderate-Dose Partial-Brain Irradiation: Neuropsychologic Outcome and Proposed Mechanisms. J Clin Oncol 13(9):2263\u0026ndash;2271. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.1995.13.9.2263\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eButler JM, Rapp S (2006) Managing the Cognitive Effects of Brain Tumor Radiation Therapy. Curr Treat Options Oncol. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11864-006-0026-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eSurma-aho O, Niemel\u0026auml; M, Vilkki J, Kouri M, Brander A, Salonen O, Paetau A, Kallio M, Pyykk\u0026ouml;nen J, J\u0026auml;\u0026auml;skel\u0026auml;inen J (2001) Adverse Long-Term Effects of Brain Radiotherapy in Adult Low-Grade Glioma Patients. Neurology 56:1285\u0026ndash;1290. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1212/wnl.56.10.1285\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eKlein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN et al (2002) Effect of Radiotherapy and Other Treatment-Related Factors on Mid-Term to Long-Term Cognitive Sequelae in Low-Grade Gliomas: A Comparative Study. Lancet Lond Engl 360:1361\u0026ndash;1368. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0140-6736(02)11398-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eDouw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH et al (2009) Cognitive and Radiological Effects of Radiotherapy in Patients with Low-Grade Glioma: Long-Term Follow-Up. Lancet Neurol 8:810\u0026ndash;818. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1474-4422(09)70204-2\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eKlein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP et al (2021) Memory in Low-Grade Glioma Patients Treated with Radiotherapy or Temozolomide: A Correlative Analysis of EORTC Study 22033\u0026ndash;26033. Neuro-Oncol 23:803\u0026ndash;811. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noaa252\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eKirman CR, North CM, Tretyakova NY, Erraguntla N, Shen H, Hays SM (2022) Use of Biomarker Data and Metabolite Relative Potencies to Support Derivation of Noncancer Reference Values Based on the Reproductive and Developmental Toxicity Effects of 1,3-Butadiene. Regul Toxicol Pharmacol 134:105239. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.yrtph.2022.105239\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003evan den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstr\u0026ouml;m P-O, Collette L, Pi\u0026eacute;rart M, Mirimanoff R et al (2005) Long-Term Efficacy of Early versus Delayed Radiotherapy for Low-Grade Astrocytoma and Oligodendroglioma in Adults: The EORTC 22845 Randomised Trial. Lancet Lond Engl 366:985\u0026ndash;990. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(05)67070-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eKiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, Nordman E, Silvestre ME, Pierart M, Karim AB (1998) Quality of Life after Radiation Therapy of Cerebral Low-Grade Gliomas of the Adult: Results of a Randomised Phase III Trial on Dose Response (EORTC Trial 22844). EORTC Radiotherapy Co-Operative Group. Eur J Cancer Oxf Engl 1990 34:1902\u0026ndash;1909. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0959-8049(98)00268-8\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eBaumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB et al (2016) Temozolomide Chemotherapy versus Radiotherapy in High-Risk Low-Grade Glioma. Lancet Oncol 17:1521\u0026ndash;1532. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1470-2045(16)30313-8\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eKarim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M et al (1996) A Randomized Trial on Dose-Response in Radiation Therapy of Low-Grade Cerebral Glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549\u0026ndash;556. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0360-3016(96)00352-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eShaw E, Arusell R, Scheithauer B, O\u0026rsquo;Fallon J, O\u0026rsquo;Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T et al (2002) Prospective Randomized Trial of Low- versus High-Dose Radiation Therapy in Adults with Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 20:2267\u0026ndash;2276. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.2002.09.126\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eDeAngelis LM, Mandell LR, Thaler TH, Kimmel DW, Galicich JH, Fuks Z, Posner JB (1989) The Role of Postoperative Radiotherapy after Resection of Single Brain Metastases. \u003cem\u003eNeurosurgery 24\u003c/em\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eLisa M (1989) DeAngelis; Jean-Yves Delattre; Jerome B. Posner Radiation-induced Dementia in Patients Cured of Brain Metastases. Neurology 39:789. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1212/WNL.39.6.789\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eNewhauser WD, Zhang R (2015) The Physics of Proton Therapy. Phys Med Biol 60:155\u0026ndash;209. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1088/0031-9155/60/8/R155\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eJhaveri J, Cheng E, Tian S (2018) Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base. Front Oncol 8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fonc.2018.00440\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eMohan R, Grosshans D (2017) Proton therapy - Present and future. Adv Drug Deliv Rev 109:26\u0026ndash;44\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eMohan R, Grosshans D (2017) Proton Therapy \u0026ndash; Present and Future. Adv Drug Deliv Rev 109:26\u0026ndash;44. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.addr.2016.11.006\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eByskov CS, Hansen CR, Dahlrot RH, Haldbo-Classen L, Haslund CA, Kj\u0026aelig;r-Kristoffersen F, Kristensen TO, Lassen-Ramshad Y, Lukacova S, Muhic A et al (2021) Treatment Plan Comparison of Proton vs Photon Radiotherapy for Lower-Grade Gliomas. Phys Imaging Radiat Oncol 20:98\u0026ndash;104. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.phro.2021.11.008\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eHarrabi SB, Nettelbladt B, Gudden C (2021) Radiation Induced Contrast Enhancement after Proton Beam Therapy in Patients with Low Grade Glioma \u0026ndash; How Safe Are Protons? Radiother Oncol 167:211\u0026ndash;218\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eLevin WP, Kooy H, Loeffler JS, DeLaney TF (2005) Proton Beam Therapy. Br J Cancer 93:849\u0026ndash;854. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/sj.bjc.6602754\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eShih HA, Sherman JC, Nachtigall LB (2015) Proton Therapy for Low-Grade Gliomas: Results from a Prospective Trial. Cancer 121:1712\u0026ndash;1719\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eBrown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer M-F et al (2021) A Prospective Phase II Randomized Trial of Proton Radiotherapy vs Intensity-Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncol 23:1337\u0026ndash;1347. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noab040\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eSherman J, Colvin M, Mancuso S, Batchelor T, Oh K, Loeffler J, Shih H (2016) Neurocognitive Effects of Proton Radiation Therapy in Adults with Low-Grade Glioma. J Neurooncol 126:157\u0026ndash;164. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11060-015-1952-5\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWorld Medical Association World Medical Association Declaration of Helsinki (2013) Ethical Principles for Medical Research Involving Human Subjects. JAMA 310:2191\u0026ndash;2194. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.2013.281053\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003ePrust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J (2018) Standard Chemoradiation in Combination with VEGF Targeted Therapy for Glioblastoma Results in Progressive Gray and White Matter Volume Loss. Neuro-Oncol 20:289\u0026ndash;291. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/nox217\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eMeyers CA, Brown PD (2006) Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors. J Clin Oncol 24:1305\u0026ndash;1309. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.2005.04.6086\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force Recommendations to Harmonise Studies of Cognitive Function in Patients with Cancer. Lancet Oncol 12:703\u0026ndash;708. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1470-2045(10)70294-1\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eDurant J, Duff K, Miller JB (2019) Regression-Based Formulas for Predicting Change in Memory Test Scores in Healthy Older Adults: Comparing Use of Raw versus Standardized Scores. J Clin Exp Neuropsychol 41:460\u0026ndash;468. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/13803395.2019.1571169\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003eEvidence-Based Indicators of Neuropsychological Change in the Individual Patient: Relevant Concepts and Methods - Google Search Available online: https://www.google.com/search?q=Evidence-Based+Indicators+of+Neuropsychological+Change+in+the+Individual+Patient%3A+Relevant+Con\u003cbr\u003ecepts+and+Methods\u0026amp;rlz=1C5GCEM_enUS1069US1072\u0026amp;oq=Evidence-\u003cbr\u003eBased+Indicators+of+Neuropsychological+Change+in+the+Individual+Patient%3A+Relevant+Con\u003cbr\u003ecepts+and+Methods\u0026amp;gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBBzQwNWowajSoAgCwAgA\u0026amp;sour\u003cbr\u003eceid=chrome\u0026amp;ie=UTF-8 (accessed on 30 October 2023).\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWinter SF, Gardner MM, Karschnia P, Vaios EJ, Grassberger C, Brussiere MR, Nikolic K, Pongpitakmetha T, Ehret F, Kaul D, Boehmerle W, Endres M, Shih H, Parsons MW, Dietrich J (2024) Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2\u0026ndash;3 gliomas. Oncologist oyae195. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/oncolo/oyae195\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eBrown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer M-F et al (2021) A Prospective Phase II Randomized Trial of Proton Radiotherapy vs Intensity-Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncol 23:1337\u0026ndash;1347. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noab040\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eWen PY, Kesari S (2008) Malignant Gliomas in Adults. N Engl J Med 359:492\u0026ndash;507. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMra0708126\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eMiller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS et al (2023) Isocitrate Dehydrogenase (IDH) Mutant Gliomas: A Society for Neuro-Oncology (SNO) Consensus Review on Diagnosis, Management, and Future Directions. Neuro-Oncol 25:4\u0026ndash;25. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/neuonc/noac207\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eEekers DB, Zegers CM, Ahmed KA, Amelio D, Gupta T, Harrabi SB, Kazda T, Scartoni D, Seidel C, Shih HA, Minniti G (2024) Controversies in neuro-oncology: focal proton versus photon radiation therapy for adult brain tumors. Neuro-Oncology Practice, p npae040\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eChen Z, Ye N, Teng C, Li X (2022) Alternations and Applications of the Structural and Functional Connectome in Gliomas: A Mini-Review. Front Neurosci 16:856808. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fnins.2022.856808\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n \u003cli\u003e\u003cspan\u003eOncology NRG (2022) National Cancer Institute (NCI. In \u003cem\u003eNCT03180502: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma\u003c/em\u003e\u003c/span\u003e\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"journal-of-neuro-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"neon","sideBox":"Learn more about [Journal of Neuro-Oncology](https://www.springer.com/journal/11060)","snPcode":"11060","submissionUrl":"https://submission.nature.com/new-submission/11060/3","title":"Journal of Neuro-Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Glioma, Radiation Therapy, Magnetic Resonance Imaging, Neurotoxicity, Cognition","lastPublishedDoi":"10.21203/rs.3.rs-4973431/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4973431/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eRadiation therapy (RT) is an integral treatment component in patients with glioma but associated with neurotoxicity. Proton RT (PRT), as compared with photon RT (XRT), reduces excess radiation to nontarget tissue. We used a retrospective method to evaluate brain imaging metrics of neurotoxicity after treatment with PRT and XRT for glioma.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eWe analyzed brain volume change in thirty-four patients with WHO grade 2\u0026ndash;3 gliomas treated with either PRT (n\u0026thinsp;=\u0026thinsp;17) or XRT (n\u0026thinsp;=\u0026thinsp;17). Both groups were carefully matched by demographic/clinical criteria and assessed longitudinally for two years post-radiotherapy. Brain volume change was measured as ventricular volume expansion in the tumor free hemisphere (contralateral to RT target) as a proxy indicator of brain volume loss. We further assessed the impact of volumetric changes on cognition in PRT patients, who completed neuropsychological testing as part of an outcome study.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eWe found significant ventricular volume increases in the contralesional hemisphere in both groups at two years post-RT (F(1, 31)\u0026thinsp;=\u0026thinsp;18.45, p\u0026thinsp;\u0026lt;\u0026thinsp;.000, partial η2\u0026thinsp;=\u0026thinsp;.373), with greater volume change observed in XRT (26.55%) vs. PRT (12.03%) (M\u0026thinsp;=\u0026thinsp;12.03%, SD\u0026thinsp;=\u0026thinsp;16.26; F(1,31)\u0026thinsp;=\u0026thinsp;4.26, p\u0026thinsp;=\u0026thinsp;0.048, partial η2\u0026thinsp;=\u0026thinsp;0.121). Although, there was no group-level change on any cognitive test in PRT treated patients, individual changes on cognitive screening, working memory, processing speed and visual memory tasks correlated with contralesional brain volume loss.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eThis study suggests progressive brain volume loss following cranial irradiation, with greater severity after XRT vs PRT. Radiation-induced brain volume loss appears to be associated with measurable cognitive changes on an individual level. Prospective studies are warranted to validate these findings and their impacts on long-term cognitive function and quality of life. An improved understanding of the structural and functional consequences of cranial radiation is essential to develop neuroprotective strategies.\u003c/p\u003e","manuscriptTitle":"Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-01 13:45:04","doi":"10.21203/rs.3.rs-4973431/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-09-15T12:00:09+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-09-11T08:45:31+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"30895539114207295268964434233136802489","date":"2024-09-03T16:58:46+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"113009316873349457395527683037434005283","date":"2024-09-03T08:19:15+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"293971246430373868974770754531909961524","date":"2024-09-01T06:49:03+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-08-31T16:18:47+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-08-31T14:04:48+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-08-31T14:03:04+00:00","index":"","fulltext":""},{"type":"submitted","content":"Journal of Neuro-Oncology","date":"2024-08-25T15:39:19+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"journal-of-neuro-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"neon","sideBox":"Learn more about [Journal of Neuro-Oncology](https://www.springer.com/journal/11060)","snPcode":"11060","submissionUrl":"https://submission.nature.com/new-submission/11060/3","title":"Journal of Neuro-Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"890a0d4d-bcd1-41d4-9138-07b90945ce91","owner":[],"postedDate":"October 1st, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-10-21T16:10:53+00:00","versionOfRecord":{"articleIdentity":"rs-4973431","link":"https://doi.org/10.1007/s11060-024-04850-9","journal":{"identity":"journal-of-neuro-oncology","isVorOnly":false,"title":"Journal of Neuro-Oncology"},"publishedOn":"2024-10-14 15:57:36","publishedOnDateReadable":"October 14th, 2024"},"versionCreatedAt":"2024-10-01 13:45:04","video":"","vorDoi":"10.1007/s11060-024-04850-9","vorDoiUrl":"https://doi.org/10.1007/s11060-024-04850-9","workflowStages":[]},"version":"v1","identity":"rs-4973431","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4973431","identity":"rs-4973431","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}